Skip to Content
We welcome visitors to our care settings while they’re wearing masks. View our updated visitor guidelines.

Mark S. Talamonti , MD

Stanton and Margaret Rogers Palmer Chairman of Surgery, NorthShore University HealthSystem
Clinical Professor of Surgery and Vice Chairman of Surgery, University of Chicago Pritzker School of Medicine

Contact Information

 847.570.1700
 847.570.2560
 847.570.2930 Fax
mailto:mtalamonti@northshore.org

Education

  • Undergraduate: 1974-78 Baccalaureate of Science, magna cum laude John Carroll University, University Heights, Cleveland, Ohio
  • Medical School: 1979-83 Doctorate of Medicine, Northwestern University Medical School, Chicago, Illinois
  • Residency: 1983-87 General Surgery Residency, Department of Surgery, Northwestern University Medical School
  • Fellowship: 1987-88 Research Fellowship, Department of Surgery, Northwestern University Medical School, Chicago, Illinois
  • Residency: 1988-89 Chief Resident in Surgery, Department of Surgery, Northwestern University Medical School, Chicago, Illinois
  • Fellowship: 1989-92 Fellowship in Surgical Oncology, Department of General Surgery, The University of Texas M.D. Anderson Cancer Center, Houston, Texas

Board Certification

  • Licensures - Active: 1984 - Illinois    036-071256
  • Licensures - Active: 1989 - Texas    J0075402
  • Specialty Board: American Board of Surgery #35234, Issued 03/14/1990; Recertification – 06/20/2002; Recertification - 12/30/2009

Research and Academic Interests

Surgical and non-surgical treatment and therapies for esophageal, pancreatic, gastric, liver, biliary tract (bile duct and gallbladder) and duodenal cancers.

Career Summary

Mark S. Talamonti, M.D. is Professor of Surgery at the University of Chicago Pritzker School of Medicine and Chairman of the Department of Surgery at NorthShore University HealthSystem. Dr. Talamonti received his undergraduate education at John Carroll University where he graduated magna cum laude and was a four-year varsity football player. He attended Northwestern University Medical School, graduating in 1983, and then completed a residency in General Surgery, which included a year as chief administrative resident, and a research fellowship in the Department of Endocrinology and Molecular Biology.  He then completed a fellowship in Surgical Oncology in the Department of Surgery at the University of Texas, MD Anderson Cancer Center in Houston. Dr. Talamonti spent the next 15 years at Northwestern University’s Feinberg School of Medicine where he rose through the ranks to become the Director of the Gastrointestinal Oncology Program, Chief of Surgical Oncology, and Professor of Surgery. In 2007, Dr. Talamonti moved to NorthShore University HealthSystem to assume the position as Chairman of the Department of Surgery.

 Dr. Talamonti’s research interests focus on combined modality clinical trials for patients with gastrointestinal malignancies. Dr. Talamonti’s clinical expertise focuses gastrointestinal surgical oncology with specific interests in pancreas and liver cancers. He has been the principal investigator or co-investigator on two recent Intergroup Trials examining the role of combined chemotherapy with external beam radiation therapy as neoadjuvant strategies prior to Whipple procedures for potentially resectable pancreatic cancers. Dr. Talamonti is the author of over 175 peer reviewed scientific publications, as well as 30 book chapters. He has authored two books on Liver Surgery and Gastrointestinal Oncology. He has served on the Editorial Board for the Annals of Surgical Oncology and the Journal of Surgical Oncology. He has held numerous positions in the Society of Surgical Oncology, and he is a member of the American Surgical Association and the Society of University Surgeons. Dr. Talamonti has received numerous awards including the Compassionate Care Award given to one physician annually who exemplifies dedication and compassion in the care of patients with cancer and life threatening illnesses. He was also honored with an Excellence in Teaching Award every year since his arrival as an attending surgeon at Northwestern University in 1992 and for the past 13 years as a faculty member at the Pritzker School of Medicine at the University of Chicago. He has had appointments as Chairman for the Medical Advisory Board for the Pancreatic Cancer Action Network (PanCAN) and to the Committee for the Pancreatic Cancer Guidelines of the National Comprehensive Cancer Center Network (NCCN). Dr. Talamonti also served as the President of the Chicago Surgical Association for 2015-2016, and President of the Western Surgical Association for 2018.  As Chairman at NorthShore, he leads a multi-faceted department which is clinically one of the most critical programs in a nationally recognized regional health system with over 900 employed physicians, six hospitals and 75 practice-entry sites.

Honors and Awards

Medical School and Residency

1987 - Alpha Omega Alpha, National Medical Honor Society

1987 - Dr. Harold L. Method Award for Outstanding Surgical Resident

1988 - Outstanding Resident Teacher Award, Northwestern University Medical School

1989 - Outstanding Resident Teacher Award, Department of Surgery, Northwestern University

1990 - Outstanding Resident Teacher Award, Northwestern University Medical School

Professional and Faculty

1995 - 2021 - Castle and Connelly Top Doctors in America and Chicago Magazine Top Doctors

2005 - 2021 - US News and World Report’s Top 1% of American Surgeons

1994 - 2006 - Outstanding Faculty Teacher Award, Department of Surgery, Northwestern University Medical School

2011 - 2021 - Outstanding Faculty Teacher Award, Department of Surgery, University of Chicago Pritzker School of Medicine

1995 - Outstanding Clinical Teacher Award, Class of 1995, Northwestern University Medical School

1996 - Compassionate Care Award, Lurie Cancer Center, Northwestern Memorial Hospital

1997 - Outstanding Faculty Mentor Award, Resident Class of 1997, Department of Surgery, Northwestern University Medical School

2000 - Robert Winter Award for Outstanding Clinical Teaching in the Surgical Clerkship, Class of 2001, Northwestern University Medical School

2002 - J. Bradley Aust Award - Best Paper by a New Member, Western Surgical Association

2005 - Vincent J. O’Connor, Sr. Award for Excellence in Teaching, As Selected by Urology Residents, Department of Urology, Northwestern University Medical School

2014 - Alpha Omega Alpha, University of Chicago Chapter, Outstanding Volunteer Clinical Faculty Teaching Award

Professional Memberships/Affiliations/Activities

  • American Association for Cancer Research
  • American Association for the Advancement of Science
  • American Medical Association
  • Chicago Society of Gastroenterology
  • American Society of Clinical Oncology 
  • American Cancer Society 
  • American College of Surgeons, Fellow
  • American Hepato-Pancreato-Biliary Association
  • American Liver Surgery Group
  • American Pancreatic Association, Inc.
  • American Surgical Association
  • Collegium Internationale Chirurgiae Digestiva
  • Illinois Surgical Society
  • Midwest Surgical Association
  • Pancreas Club
  • Society for Surgery of the Alimentary Tract
  • Society of Surgical Oncology
  • Society of University Surgeons 
  • Southwestern Surgical Congress
  • Western Surgical Association

Scholarly Work

Refereed Journal Papers:

  1. Talamonti MS, LoCicero J, Sanders JE, Michaelis LL:  Early reexploration for excessive postoperative bleeding lowers wound complication rates in open heart surgery.  Am Surg 53:102-104, 1987. (First author, responsible for data and manuscript preparation)
  2. Talamonti MS, Joehl RJ, Dawes LG, Nahrwold DL:  Primary gastrointestinal lymphomas:  A case for surgical therapy.  Arch Surg 125:972-977, 1990. (First author, responsible for data and manuscript preparation)
  3. Talamonti MS, Roh MS, Curley SA, Gallick GE:  The c-src oncogene participates in the development of human colorectal liver metastases.  Surg Forum 42:422-424, 1991. (First author, responsible for data and manuscript preparation)
  4. Fuhrman GM, Talamonti MS, Curley SA:  Sphincter-preserving extended resection for locally advanced rectosigmoid carcinoma involving the urinary bladder.  J Surg Oncol 50(2):77-80, 1992. (Co-author, responsible for data and manuscript preparation)
  5. Talamonti MS, Roh MS, Curley SA, Gallick GE:  Increase in activity and level of pp60-c-src in progressive stages of human colorectal cancer.  J Clin Invest 91:53-60, 1993. (First author, responsible for data and manuscript preparation)
  6. Termuhlen PM, Curley SA, Talamonti MS, Saboorian MH, Gallick GE:  Site-specific differences in pp60c-src activity in human colorectal metastases.  J Surg Research 54:293-298, 1993. (Co-author, responsible for data and manuscript preparation)
  7. Lyster MT, Benson AB, Vogelzang R, Talamonti MS:  Chemoembolization:  alternative for hepatic tumors.  Contemp Oncol 3:17-28, 1993. (Senior author, manuscript preparation)
  8. Talamonti MS, Shumate CR, Carlson GW, Curley SA:  Locally advanced colorectal cancer involving the urinary bladder:  management, complications, and survival.  Surgery, Obst & Gyn 177-481-487, 1993. (First author, responsible for data and manuscript preparation)
  9. Yang EYT, Joehl RJ, Talamonti MS:  Cystic neoplasms of the pancreas.  J Am Coll Surg 179:747-757, 1994. .  (Senior author, developed hypothesis, manuscript preparation)
  10. Termuhlen PM, Curley SA, Talamonti MS, Saboorian MH, and Gallick GE, Site-specific Differences in pp60c-src  Activity in Human Colorectal Metastases.  Yearbook of Surgery 94:363-4, 1994.  (First faculty author, developed hypothesis, manuscript preparation)
  11. Singh CJ, Haines GK, Talamonti MS, Radosevich JA:  Expression of p68 in human colon cancer.  Tumor Biol 16:281-289, 1995. . (Co-author, mentor, manuscript preparation)
  12. Brenin DR, Talamonti MS, Yang EST, Sener SF, Haines GK, Joehl RJ, Nahrwold DL:  Cystic neoplasms of the pancreas:  a clinicopathologic study, including DNA flow cytometry.  Arch Surg 130:1048-1054, 1995. . (First faculty author, mentor, developed hypothesis, manuscript preparation)
  13. Talamonti MS, Kozlowski K, Kwaan HC, Nahrwold DL:  Endothelial cell invasion is enhanced by the urokinase-type plasminogen activator system in colon cancer cell lines.  Surg Forum 46: 206-208, 1995. (Primary author, developed hypothesis, performed research,  manuscript preparation)
  14. Martenson JA, Lipsitz S, Wagner H, Kaplan EH, Otteman L, Schuchter L, Mansour EG, Talamonti MS, Benson AB:  Initial results of a phase II trial of high dose radiation therapy, 5-fluorouracil, and cisplatin for patients with anal cancer (E4292):  an eastern cooperative study.   Int J Radiat Oncol Biol Phys 35:745-749, 1996.  (Co-author, developed hypothesis, manuscript preparation)
  15. Haines GK, Cajulis R, Hayden R, Duda R, Talamonti MS, Radosevich JA:  Expression of the double-stranded RNA-dependent protein kinase (p68) in human breast tissues.  Tumor Biol 17:5-12, 1996. (Collaborator, manuscript review)
  16. Volm MD, Talamonti MS, Thangavelu M, Gradishar WJ:  Pituitary adenoma and bilateral male breast cancer:  an unusual association.  J Surg Onc 64:74-78, 1997. (First faculty author, mentor, manuscript preparation)
  17. Sturgis CD, Baur-Marsh E, Yokko H, Talamonti MS, Barch DH.  Crohn’s disease of the terminal ileum masquerading as an adenomatous polyp of the ileocecal valve.  Gastrointestinal Endoscopy 1998. (Co-author, manuscript review)
  18. Fang J, Hussong J, Roebuck BD, Talamonti MS, Rao MS.  Atypical acinar cell foci in human pancreas: morphological and morphometric analysis.  International Journal of Pancreatology 22:127-130, 1997. (Co-author, manuscript review)
  19. Hussong J, Talamonti MS, Rao MS.  p53 protein overexpression in infiltrating ductal carcinoma of female breast and its association with lymph node metastasis. Oncology Reports 4:917-920, 1997. (First faculty author, mentor, manuscript preparation)
  20. Tellez C, Benson AB III, Lyster M, Talamonti MS, Braun M, Nemcek A, Vogelzang R.  A Phase II trial of chemoembolization for the treatment of metastatic colorectal carcinoma to the liver and review of the literature.  Cancer 82: 1250-1259, 1998. (Collaborator, mentor, manuscript review)
  21. Brenin CM, Talamonti MS, Small WJ, Gradishar WJ.  Radiation-induced sarcoma following treatment of breast cancer: a case report and review of the literature. Cancer Control 5:338-345, 1998. (First faculty author, mentor, developed hypothesis, manuscript preparation)
  22. Briggman J, Genduso R, Camara C, Healy B, Merrifield S, Shapiro K, Roos R, Lefter J, Wu Y, Elder E, and Talamonti MS.  NuMA: A New Biomarker for the Detection of Low Stage Colorectal Cancer. Anticancer Research 19: 2411-2414, 1999. (Senior author, developed hypothesis, manuscript preparation)
  23. Chlenski A, Ketels KK, Tsao MS, Talamonti MS, Koutnikova H, Anderson MR, Scarpelli DG. Tight junction protein ZO-2 is differentially expressed in normal pancreatic ducts compared to human pancreatic adenocarcinoma. Int. J. Cancer 82:137-144, 1999. (Collaborator, mentor, manuscript review)
  24. Chlenski A, Ketels KK, Engeriser JL, Talamonti MS, Tsao MS, Koutnikova H, Oyasu R, Scarpelli DG.  ZO-2 gene alternative promoters in normal and neoplastic human pancreatic duct cells. Int. J. Cancer 83:349-58, 1999. (Collaborator, mentor, manuscript review)
  25. Sullivan M, Talamonti MS, Sithanandam K, Joob A, Pelzer H. Joehl RJ.  Results of gastric interposition for reconstruction of the pharyngoesophagus.  Surgery 126:666-672, 1999. (First faculty author, mentor, developed hypothesis, manuscript preparation)
  26. Morrow M, Rademaker AN, Bethke KP, Talamonti MS, Dawes LG, Clausen J, Hansen N.  Learning sentinel node biopsy: results of a prospective randomized trial of two techniques. Surgery 126:714-722, 1999. (Co-author, manuscript review)
  27. Talamonti MS, Catalano PJ, Vaughn DJ, Whittington R, Beauchamp RD, Berlin J, Benson AB.  An ECOG phase I trial of protracted venous infusion 5-fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: a regimen with unexpected early toxicity. J Clin Oncol 18:3384-3389, 2000. (Primary author, developed hypothesis, manuscript preparation)
  28. Yao KA, Talamonti MS, Langella RL, Schindler NM, Rao S, Small WS, Joehl RJ.  Primary Gastrointestinal sarcomas: Analysis of prognostic factors and results of surgical management. Surgery 128:604-610, 2000. (First faculty author, mentor, developed hypothesis, manuscript preparation)
  29. Compagnoni GM, Talamonti MS, Joob A, Ergun GA, and Rao S.  Esophageal leiomyomatosis in a woman with a history of vulvar leiomyoma and Barrett’s esophagus: A case report and review of the literature. Digestive Surgery 17:306-309, 2000. (First faculty author, mentor, developed hypothesis, manuscript preparation)
  30. Tajuddin A, Braun MA, Nemcek AA, Talamonti MS, Vogelzang RL, Benson AB.  Pseudoaneurysm of the hepatic artery: a complication of the implantable intra-arterial infusion pump in a patient with metastatic colon cancer.  Digestive Surgery 17, 2000. (Co-author, mentor, developed hypothesis, manuscript preparation)
  31. Chlenski A, Ketels K.V, Korovaitseva GI, Talamonti MS, Oyasu R, Scarpelli DG. Organization and expression of the human ZO-2 gene (tjp-2)in normal and neoplastic tissues. Biochim.Biophys.Acta, 1493: 319-324, 2000. (Collaborator, mentor, manuscript review)
  32. Okonkwo A, Musunuri S, Talamonti MS, Benson AB, Small WA, Stryker SJ, Rao SM.  Molecular markers and prediction of response to chemoradiation in rectal cancer.  Oncology Reports 8:497-500, 2001. (Co-author, mentor, manuscript review)
  33. Bilimoria MM, Parsons WG, Small W, Talamonti MS. Pylorus-preserving pancreaticoduodenectomy in a patient with ampullary carcinoma and situs inversus. Surgery 130:521-524, 2001. (Senior author, mentor, manuscript preparation)
  34. Eisemon N, Stucky-Marshall L, Talamonti MS. Screening for Colorectal Cancer.  Gastroenterology Nursing 24:12-19, 2001. (Senior author, mentor, manuscript preparation)
  35. Yao KA, Talamonti MS, Nemcek A, Angelos P, Chrisman H, Skarda J, Benson AB, Rao S, Joehl RJ.  Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors.  Surgery 130:677-685, 2001. (First faculty author, mentor, developed hypothesis, manuscript preparation)
  36. Pappas S, Diaz L, Talamonti MS, A cystic pancreatic mass discovered in a patient with ileocecal carcinoid.  Arch. Pathol Lab Med 126:229-230, 2002. (Senior author, mentor, manuscript preparation)
  37. Talamonti MS, Goetz LH, Rao S, Joehl RJ, Primary cancers of the small bowel: Analysis of prognostic factors and results of surgical management.  Arch Surg 137:564-571, 2002. (Primary author, developed hypothesis, manuscript preparation)
  38. Bentrem DJ, Angelos P, Talamonti MS, Nayar R. Is preoperative investigation of the thyroid justified in patients undergoing parathyroidectomy for hyperparathyroidism? Thyroid 12:1109-1112, 2002. (Co-author, mentor, manuscript review)
  39. Sun X, Gong Y, Talamonti MS, Rao MS.  Expression of cell adhesion molecules, CD44s and E-cadherin, and microvessel density in carcinoid tumors.  Mod Path 15: 1333-1338, 2002. (Collaborator, mentor, manuscript review)
  40. Talamonti MS, Kim SP, Yao KA, Wayne JD, Feinglass JM, Bennett CL, Rao MS. Surgical outcomes of gastric carcinoma patients: the importance of primary tumor location and microvessel invasion.  Surgery 134:720-729, 2003. (Primary author, developed hypothesis, manuscript preparation)
  41. Kim SP, Feinglass J, Bennett CL, Lyons T, Simon C, Weinberg M, Talamonti MS.  Merging claims databases with a tumor registry to evaluate variations in cancer mortality: results from a pilot study of 698 colorectal cancer patients treated at one hospital in the 1990s.  Cancer Invest, 22: (2), 225-233, 2004. (Senior author, mentor, developed hypothesis, manuscript preparation)
  42. Shivnani AT, Small W, Benson A, Rao MS, Talamonti MS.  Adenocarcinoma arising in rectal duplication cyst: case report and review of the literature. Am Surg 70: (11) 1007-1009, 2004. (Senior author, mentor, manuscript preparation)
  43. Kennedy T, Talamonti MS, Ding XZ, Ujiki M, Ternent C, Bell RH.  Lipoxygenase expression in colon polyps and inhibition of colon cancer growth by lipoxygenase blockade.  J Amer Col of Surg, 199-3:78, 2004 (Co-author, mentor, manuscript review)
  44. Yoshida S, Yokota T, Ujiki M, Ding X-Z, Pelham C, Adrian TE, Talamonti MS, Bell RH, Denham E.  Pancreatic cancer stimulates pancreatic stellate cell proliferation and TIMP-1 production through the MAP Kinase pathway.  Biochem and Biophys Res Commun (BBRC) 323:1241-1245, 2004.  (Collaborator, mentor, manuscript review)
  45. Hennig R, Ventura J, Segersvard R, Ward E, Ding X-Z, Sambasiva MR, Jovanovic BD, Iwamura T, Talamonti MS, Bell RH, Adrian TE.  LY293111 Improves efficacy of gemcitabine therapy on pancreatic cancer in fluorescent orthotopic model in athymic mice.  Neoplasia 10:1-9, 2005. (Collaborator, mentor, manuscript review)
  46. Chan C-Y, Salabat MR, Ding X-Z, Kelly DL, Talamonti MS, Bell RH, Adrian TE.  Identification and in silico characterization of a novel gene: TPA induced trans-membrane protein.  Biochem and Biophys Res Commun. 329:755-64, 2005. (Collaborator, mentor, manuscript review)
  47. Ding X-Z, Talamonti MS, Bell RH, Adrian TE.  A novel anti-pancreatic cancer agent, LY29311.   Anti-cancer Drugs 16(5): 467-73, 2005. (Collaborator, mentor, manuscript review)
  48. Henning R, Grippo P, Ding X-Z, Rao SM, Buchler MW, Friess H, Talamonti MS, Bell RH, Adrian TE.  5-Lipoxygenase, a marker for early pancreatic intraepithelial neoplastic lesions. Cancer Res 65:6011-6016, 2005. (Collaborator, mentor, manuscript review)
  49. Yoshida S, Ujiki M, Ding X-Z, Pelham C, Talamonti MS, Bell RH, Denham W, Adrian TE.  Pancreatic stellate cells (PSCs) express cyclooxygenase-2 (COX-2) and pancreatic cancer stimulates COX-2 in PSCs. Mol Cancer 5; 4:27, 2005. (Collaborator, mentor, manuscript review)
  50. Tong WG, Ding X-Z, Talamonti MS, Bell RH, Adrian TE.  LTB4 stimulates growth of human pancreatic cancer cells via MAPL and PI-3 kinase pathways.  Biochem Biophys Res Cummun 335(3): 949-56, 2005. (Collaborator, mentor, manuscript review)
  51. Tempero MA, Behrman S, Ben-Josef E, Benson AB, Cameron JL, Casper ES, Hoffman JP, Karl RC, Kim P, Koh WJ, Kuvshinoff BW, Melvin MS, Muscarella P, Sasson AR, Shibata S, Schrieve DC, Talamonti MS, Tyler DS, Vickers SM, Warren RS, Willett C, Wolff RA: National Comprehensive Network.  Pancreatic adenocarcinoma: clinical practice guidelines in oncology.  J Natl Compr Canc Netw. 3(5): 598-626, 2005. (Collaborator, manuscript review)
  52. Lim SJ, Alasadi R, Wayne JD, Rao S, Rademaker A, Bell RH, Talamonti MS.  Pre-operative evaluation of pancreatic cystic lesions: Cost benefit analysis and proposed management algorithm. Surgery 138:672-680, 2005. (Senior author, mentor, developed hypothesis, manuscript preparation)
  53. Ujiki MB, Milam B, Ding XZ, Roginsky AB, Salabat MR, Talamonti MS, Bell RH, Adrian TE.  A novel peptide sansalvamide analogue inhibits pancreatic cancer cell growth through G0/G1 cell-cycle arrest. Biochem Biophys Res Cummun 340(4): 1224-8, 2006. (Collaborator, mentor, manuscript review)
  54. Talamonti MS, Small W, Mulcahy MF, Attaluri V, Colletti L, Zalupski MM, Hoffman J, Freedman GM, Kinsella TJ, McGinn CJ.  A multi-institutional phase II trial of preoperative full dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma.  Ann Surg Oncol 13(2):150-158, 2006. (Primary author, developed hypothesis, manuscript preparation)
  55. Kennedy T, Preczewski L, Stocker SJ, Rao SM, Parsons WG, Wayne JD, Bell RH, Talamonti MS.  Incidence of benign inflammatory disease in patients undergoing Whipple procedure for clinically suspected carcinoma: A single institution experience.  Am J Surg 191:437-441, 2006. (Senior author, mentor, developed hypothesis, manuscript preparation)
  56. Salabat MR, Ding XZ, Flesche JB, Ujiki MB, Robin TP, Talamonti MS, Bell RH, Adrian TE. On the mechanisms of 12-otetradecanoylphorbol-13-acetate-induced growth arrest in pancreatic cancer cells. Pancreas 33(2): 148-55, 2006. (Collaborator, mentor, manuscript review)
  57. Nicolas MM, Talamonti MS and Rao S. Mesothelial cyst of the pancreas.  Annals of Diagnostic Pathology 10:371-373, 2006. (Collaborator, manuscript review)
  58. Shivnani AT, Small W, Stryker SJ, Kiel KD, Lim S, Halverson AL, Talamonti MS. Preoperative chemoradiation for rectal cancer: results of multimodality management and analysis of prognostic factors. Am J Surg 193:389-394, 2007. (Senior author, mentor, developed hypothesis, manuscript preparation)
  59. Golkar L, Ding XZ, Ujiki MB, Salabat MR, Kelly DL, Scholtens D, Fought AS, Bentrem DJ, Talamonti MS, Bell RH, Adrian TE.  Resveratrol inhibits pancreatic cancer cell proliferation through transcriptional induction of macrophage inhibitory Cytokine-1 (MIC-1). J Surg Res 138:163-169, 2007. (Collaborator, mentor, manuscript review)
  60. Tong WG, Ding XZ, Talamonti MS, Bell RH, Adrian TE. Leukotriene B4 receptor antagonist LY293111 induces S-phase cell cycle arrest and apoptosis in human pancreatic cancer cells.  Anticancer Drugs June, 18(5):535-41, 2007. (Collaborator, mentor, manuscript review)
  61. Bilimoria KY, Bentrem DJ, Ko CY, Ritchey J, Stewart AK, Talamonti MS.  Validation of the 6(th) edition AJCC pancreatic cancer staging system: report from the National Cancer Data Base.  Cancer 110(4):738-744, 2007. (Senior author, mentor, developed hypothesis, manuscript preparation)
  62. Bilimoria K, Bentrem DJ, Ko CY, Tomlinson JS, Stewart AK, Winchester DP, Talamonti MS.  Multimodality therapy for pancreatic cancer in the U.S.; utilization, outcomes, and the effect of hospital volume: Cancer 110(6): 1227-34, 2007. (Senior author, mentor, developed hypothesis, manuscript preparation)
  63. Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DK, Talamonti MS. National Failure to Operate on Early Stage Pancreatic Cancer. Ann Surg. 246(2):173-180, 2007. (Senior author, mentor, developed hypothesis, manuscript preparation)
  64. Bilimoria KY, Stewart AK, Tomlinson JS, Gay EG, Talamonti MS, Ko CY, Bentrem DJ.  Impact of adjuvant radiation on survival: A note of caution when using cancer registry data to evaluate adjuvant treatments. Ann Surg Oncol 14(12): 3321-3327, 2007. (Co-author, mentor, manuscript preparation)
  65. Bilimoria KY, Bentrem DJ, Merkow RP, Stewart AK, Talamonti MS. Application of the pancreatic adenocarcinoma staging system to pancreatic neuroendocrine tumors: A report from the National Cancer DataBase.  J Am Coll Surg 205(4): 558-563, 2007. (Senior author, mentor, developed hypothesis, manuscript preparation)
  66. Bilimoria KY, Talamonti MS, Ko CY, Stewart AK, Tomlinson JS, Bentrem DJ.  Clinicopathologic features of pancreatic neuroendocrine tumors: Analysis of 9,821 patients from the National Cancer Data Base.  J Gastrointest Surg 11(11): 1460-1469, 2007. (Co-author, mentor, developed hypothesis, manuscript preparation)
  67. Blum MG, Bilimoria KY, de Hoyos AL, Talamonti MS, Wayne JD, Adley B. Surgical considerations for the management and resection of esophageal gastrointestinal stromal tumors.  Ann Thorac Surg 84(5): 1717-1723: 2007. (Collaborator, mentor, manuscript review)
  68. Bilimoria KY, Bentrem DJ, Tomlinson JS, Merkow RP, Stewart AK, Prystowsky JB, Ko CY, Talamonti MS. Does the VA compare? Quality of pancreatic cancer care at VA vs. Non-VA hospitals.  Am J Surg 194(5): 588-593: 2007. (Senior author, mentor, developed hypothesis, manuscript preparation)
  69. Bilimoria KY, Bentrem DJ, Linn JG, Freel A, Yeh JJ, Stewart AK, Winchester DP, Ko CY, Talamonti MS, Sturgeon C.  Underutilization of total thyroidectomy for papillary thyroid cancer in the United States. Surgery 142(6):906-913, 2007. (Collaborator, mentor, manuscript review)
  70. Bilimoria KY, Bentrem DJ, KoCY, Stewart AK, Winchester DP, Talamonti MS, Sturgeon C.  Extent of surgery affects survival for papillary thyroid cancer. Ann Surg, Sept 246(3): 375-384, 2007. (Collaborator, mentor, manuscript review)
  71. Tempero MA, Arnoletti JP, Ben-Josef E, Bhargava P, Casper ES, Kim P, Malafa MP, Nakakura EK, Shibata S, Talamonti MS, Wang H, Willett C: National Comprehensive Network.  Pancreatic adenocarcinoma: clinical practice guidelines in oncology.  J Natl Compr Canc Netw. 5(10): 998-1033, 2007. (Collaborator, manuscript review)
  72. Yang AD, Melstrom LG, Bentrem DJ, Ujiki, MB, Wayne JD, Bell RH, Rao SM, Talamonti MS. Outcomes after pancreatectomy for intraductal papillary mucinous neoplasms of the pancreas – An institutional experience. Surgery 142(4): 529-537, 2008. (Senior author, mentor, developed hypothesis, manuscript preparation)
  73. Bilimoria KY, Bentrem DJ, Stewart AK, Talamonti MS, Winchester DP, and Ko CY.   Adequacy and importance of lymph node evaluation for colon cancer in the elderly.  J Am Coll Surg 206 (2): 247-254, 2008. (Collaborator, mentor, manuscript review)
  74. Bilimoria KY, Bentrem DJ, Stewart AK, Freel A, Winchester DP, Russell TR,   Talamonti MS, and Ko CY.   Impact of tumor location on nodal evaluation for colon cancer.  Dis Colon Rectum 51(2): 154-161, 2008. (Collaborator, mentor, manuscript review)
  75. Bilimoria KY, Talamonti MS, Tomlinson JS, Stewart AK, Ko CY, Bentrem DJ.  Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors: Analysis of 3,851 patients. Ann Surg 246(3): 490-500, 2008. (Co-author, mentor, developed hypothesis, manuscript preparation)
  76. Small W, Berlin J, Freedman GM, Lawrence T, Talamonti MS, Mulcahy MF, Chakravaarthy AB, et al.  Full-dose gemcitabine with concurrent radiation therapy in patients with non-metastatic pancreatic cancer: a mulitcenter phase II trial. J Clin Oncol 26: 942-947, 2008. (Co-author, mentor, developed hypothesis, manuscript preparation)
  77. Sato KT, Lewandowski RJ, Mulcahy MF, Talamonti MS, et al., Use of Yttrium-90 microspheres for the treatment of unresectable liver metastases in chemorefractory patients: toxicities, response and survival. Radiology 247 (2):507-515, 2008. (Collaborator, manuscript review)
  78. Bilimoria KY, Bentrem DJ, Ko CY, Lange JR, Talamonti MS, Winchester DP, Balch, CM, Wayne JD.  Complete lymph node dissection for sentinel node-positive melanoma: variable adherence with consensus guidelines in the United States.  Ann Surg Oncol 15 (6): 1566-1576, 2008. (Collaborator, mentor, manuscript review)
  79. Gawron AJ, Gapstur SM, Fought AJ, Talamonti MS, Skinner HG. Sociodemographic and tumor characteristics associated with pancreatic cancer   surgery in the United States.  J Surg Oncol Jun 1; 97(7): 578-582, 2008. (Co-author, mentor, developed hypothesis, manuscript preparation)
  80. Bilimoria KY, Talamonti MS, Wayne JD, Tomlinson JT, Stewart AK, Ko CY, and Bentrem DJ.  Impact of hospital type and volume on lymph node evaluation for gastric and pancreatic cancer.  Arch Surg 143(7): 671-678, 2008. (Co-author, mentor, developed hypothesis, manuscript preparation)
  81. Golkar L, Salvino MJ, Blum MG, Talamonti MS, Bentrem DJ, Angelos PA, Printen K J.  Adenocarcinoma of the gastroesophageal junction after bariatric surgery.  Am J Surg  196(1):135-138, 2008. (Collaborator, mentor, manuscript review)
  82. Abbott DE, Halverson AL, Wayne JD, Kim JY, Talamonti MS, Dumanian, GA.  The oblique rectus abdominal myocutaneous flap for complex pelvic wound reconstruction. Dis Colon Rectum 51(8): 1237-1241, 2008. (Co-author, mentor, manuscript preparation)
  83. Bilimoria KY, Bentrem DJ, Ko CY. Stewart AK, Winchester DP, Talamonti MS, Halverson AL.  Squamous cell carcinoma of the anal canal: utilization and outcomes of recommended treatment in the United States.  Ann Surg Oncol. 15(7): 1948-1958, 2008. (Co-author, mentor, manuscript preparation)
  84. Kim L, Liao J, Zhang M, Talamonti MS, Bentrem DB, Rao S, Yang AG. Clear cell carcinoma of the pancreas: histopathologic features and a unique biomarker: hepatocyte nuclear factor-1 beta.  Mod Path 21(9): 1075-1083, 2008. (Collaborator, mentor, manuscript review)
  85. Kooby DA, Gillespie T, Bentrem DB, Nakeeb A, Schmidt MC, Merchant NB, Parikh AA, Martin RC, Scoggins CR, Ahmad S, Kim HJ, Park J, Johnstons F, Strouch MJ, Mense A, RymerJ, McClain R, aStrasberg SM, Talamonti MS, Staley CA, McMaster KM, Lowy AM, Byrd-Sellers J, Wood WC, Hawkins WG.  Left-sided pancreatectomy: a multicenter comparison of laparoscopic and open approaches.  Ann Surg 248(3): 438-446. 2008. (Collaborator, manuscript preparation and review)
  86. Bilimoria KY, Bentrem DJ, Feinglass JM, Stewart AK, Winchester DP, Talamonti MS. Directing surgical quality improvement initiatives in the United States: Comparison of perioperative mortality and long-term survival for cancer surgery.  J Clin Oncol 26 (28): 4626-4633. 2008. (Senior author, mentor, developed hypothesis, manuscript preparation)
  87. Bilimoria KY, Bentrem DJ, Stewart AK, Winchester DP, Russell TR, Talamonti MS, Ko CY. Lymph node evaluation as a surgical quality indicator for colon cancer: The first national hospital report card. J Natl Cancer Inst. 100 (18): 1310-1317. 2008. (Co-author, mentor, manuscript preparation)
  88. Bilimoria KY, Talamonti MS, Sener SF, Bilimoria MM, Stewart AK, Winchester DP, Ko CY, Bentrem DJ.  Impact of hospital volume on margin status for pancreatic cancer resections in the United States. J Am Coll Surg 207: 510-519, 2008. (Co-author, mentor, developed hypothesis, manuscript preparation)
  89. Melstrom LG, Bentrem DJ, Salabat MR, Kennedy TJ, Ding XZ, Talamonti MS, et   al.  Overexpression of 5-lipooxygenase in colon polyps and cancer and the effect of 5-LOX inhibitors in vitro and in a murine model. Clin Cancer Res. 14(20): 6525-6530, 2008. (Collaborator, mentor, manuscript review)
  90. Schmidt CM, Matos JM, Bentrem DJ, Talamonti MS, Lillemoe KD, Bilimoria KY.  Acinar cell carcinoma of the pancreas in the United States: prognostic factors and comparison to ductal adenocarcinoma.  J. Gastointest Surg. 12:2078-2086, 2008. (Collaborator, mentor, manuscript preparation)
  91. Bilimoria KY, Bentrem DJ, Wayne JD, Ko CY, Bennett CL, Talamonti MS.  Small bowel cancer in the United States: changes in epidemiology, treatment and survival over the last 20 years.  Ann Surg 249 (1):63-72, 2009. (Senior author, mentor, manuscript preparation)
  92. Melnikov AA, Scholtens D, Talamonti MS, Bentrem DJ, Levenson VV.  Differential methylation profile of plasma DNA as a possible biomarker for pancreatic cancer.  J Surg Oncolo 99 (2): 119-122, 2009. (Co-author, developed hypothesis, manuscript preparation)
  93. Mulcahy MF, Lewandowski RJ, Ibrahim SM, Sato KT, Ryu RK, Atassi B, Newman S, Talamonti MS, Omary RA, Benson AB, Salem R.   Radioembolization of colorectal hepatic metastases using yttrium-90 microspheres.  Cancer 1849-1858, 2009. (Co-author, mentor, developed hypothesis, manuscript preparation)
  94. Bilimoria KY, Bentrem DJ, Lillemoe KD, Talamonti MS, Ko Cy.  Assessment of pancreatic cancer care in the United States based on formally developed quality indicators.  J Natl Cancer Inst 101:848-859, 2009. (Co-author, mentor, developed hypothesis, manuscript preparation)
  95. Pitt SC, Pitt HA, Baker MS, Christians K, Touzios JG, Kiely JM, Weber SM, Wilson SD, Howard TJ, Talamonti MS, Rikkers LF. Small pancreatic and periampullary neuroendocrine tumors: resect or enucleate?  J Gastrointest Surg. Sep;13(9):1692-8. 2009. (Co-author, developed hypothesis, manuscript preparation)
  96. Baker MS, Bentrem DJ, Ujiki MB, Stocker S, Talamonti MS. A prospective single institution comparison of peri-operative outcomes for laparoscopic and open distal pancreatectomy. Surgery 146(4): 635-645, 2009. (Co-author, mentor, developed hypothesis, manuscript preparation)
  97. Liggett T, Melnikov A, Yi QL, Replogle C, Brand R, Kaul K, Talamonti M, Abrams RA, Levenson V. Differential methylation of cell-free circulating DNA among patients with pancreatic cancer versus chronic pancreatitis.  Cancer, 116(7):1674 -1680, 2010.  (Collaborator, manuscript preparation)
  98. Cao W, Adley BP, Liao J, Lin X, Talamonti M, Bentrem DJ, Rao SM, Yang GY.  Mucinous nonneoplastic cyst of the pancreas: apomucin phenotype distinguishes this entity from intraductal mucinous neoplasm.  Hum Pathol, Apr 41(4): 513-521, 2010. (Collaborator, manuscript preparation)
  99. Bilimoria KY, Bentrem DJ, Talamonti MS, Stewart AK, Winchester DP, Ko CY.  Risk-based selective referral for cancer surgery: a potential strategy to improve perioperative outcomes.  Ann Surg. 251(4): 708-16, 2010.  (Co-author, mentor, manuscript preparation)
  100. Fronza JS, Bentrem DJ, Baker MS, Talamonti MS, Ujiki MB. Laparoscopic distal pancreatectomy using radiofrequency energy.  Am J Surg 199(3): 401-404, 2010. (Senior author, mentor, manuscript preparation)
  101. Landry J, Catalona PJ, Staley C, Harris W, Hoffman J, Talamonti M, Xu N, Cooper H, Benson AB.  Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma.  J Surg Oncol 101(7): 587-92, 2010. (Co-author, mentor, developed hypothesis, manuscript preparation)
  102. Stratford JK, Bentrem DJ, Anderson JM, Fan C, Volmar KA, Marron JS, Routh ED, Caskey LS, Samuel JC, Der CJ, Thorne LB, Calvo BF, Kim HJ, Talamonti MS, Donahue CA, Hollingsworth MA, Perou CM, Yeh JJ.  A six-gene signature predicts survival of patients with localized pancreatic adenocarcinoma.  PLoS Medicine 7(7): e1000307, 1-9, 2010.  (Collaborator, manuscript preparation)
  103. Vern-Gross TZ, Shivani AT, Chen K, Lee CM, Tward JD, MacDonald OK, Crane CH, Talamonti MS, Munoz LL, Small W Jr.  Survival outcomes in resected extrahepatic cholangiocarcinoma: effect of adjuvant radiotherapy in a surveillance, epidemiology, and end-result analysis. Int J Radiat Oncol Biol Phys 81(1):189-198, 2011. (Senior author, manuscript preparation)
  104. Baker MS, Bentrem DJ, Ujiki MB, Stocker S, Talamonti MS. Adding days spent in readmission to the initial postoperative length of stay limits the perceived benefit of laparoscopic distal pancreatectomy when compared with open distal pancreatectomy. Am J Surg. Mar;201(3):295-300, 2011. (Senior author, manuscript preparation)
  105. Bilimoria KY, Ko CY, Tomlinson JS, Stewart AK, Talamonti MS, Hynes DL, Winchester DP, Bentrem DJ. Wait times for cancer surgery in the United States: trends and predictors of delays. Ann Surg. Apr 253(4): 779-85, 2011. (Co-author, mentor, manuscript preparation)
  106. Chakravarthy AB, Catalano PJ, Martenson JA, Mondschein JK, Wagner H, Mansour EG, Talamonti MS, Benson AB.  Long-term follow-up of a phase II trial of high-dose radiation with concurrent 5-fluorouracil and cisplatin in patients with anal cancer (ECOG E4292). Int J Radiat Oncolo Biol Phys. Nov 15:81(4):e607-13, 2011.  (Co-investigator, manuscript preparation)
  107. Small W, Mulcahy MM, Rademaker A, Bentrem DJ, Benson AB, Weitner WW, Talamonti MS.  Phase II trial of full-dose gemcitabine and bevacizumab in combination with attenuated three-dimensional conformal radiotherapy in patients with localized pancreatic cancer.  Int J Radiat Oncolo Biol Phys. June 80(2): 476-482, 2011. (Senior author, study design, manuscript preparation)
  108. Yetasook AK, Leung D, Howington JA, Talamonti MS, Zhao J, Carbray JM, Ujiki MB. Laparoscopic ischemic conditioning of the stomach prior to esophagectomy. Dis Esophagus Jul 26(5):479-86, 2013. (Co-author, mentor, manuscript preparation)
  109. Grippo PJ, Fitchev PS, Bentrem DJ, Melstrom LG, Dangi-Garimella S, Krantz SB, Heiferman MJ, Chung C, Adrian K, Cornwell ML, Flesche JB, Rao SM, Talamonti MS, Munshi HG, Crawford SE. Concurrent PEDF deficiency and Kras mutation induce invasive pancreatic cancer and adipose-rich stroma in mice. Gut. 2012 Oct;61(10):1454-64. doi: 10.1136/gutjnl-2011-300821. (Co-author, manuscript preparation)
  110. Hardacre JM, Mulcahy M, Small W, Talamonti MS, Obel J, Krishnamurthi S, Rocha-Lima CS, Safran H, Lenz HJ, Chiorean EG. Addition of Algenpantucel-L Immunotherapy to Standard Adjuvant Therapy for Pancreatic Cancer: A Phase II Study. J Gastrointest Surg doi: 10.1007/s11605-012-2064-6 Epub 2012 Nov 15. (Co-author, manuscript preparation)
  111. Baker MS, Sherman KL, Stocker S, Hayman AV, Bentrem DJ, Prinz RA, Marsh RD, Talamonti MS. Defining quality for distal pancreatectomy: does the laparoscopic approach protect patients from poor quality outcomes? J Gastrointest Surg 2013 Feb; 17(2):272-80. (Senior author, study design, manuscript preparation)
  112. Hayman AV, Stocker SJ, Baker MS, Bentrem DJ, Prinz RA, marsh RD, Talamonti MS. CA 19-9 non-production is associated with poor survival after resection of pancreatic adenocarcinoma. Am J Clin Oncol. 2013 Feb 20. Epub ahead of print. (Senior author, study design, manuscript preparation)
  113. Cherenfant J, Stocker SJ, Gage MK, Du H, Thurow TA, Odeleye M, Schimpke SW, Kaul KL, Hall CR, Lamzabi I, Gatttuso P, Winchester DJ, Marsh RW, Roggin KK, Bentrem DJ, Baker MS, Prinz RA, Talamonti MS. Predicting aggressive behavior in nonfunctioning pancreatic neuroendocrine tumors. Surgery October,154(4):785-793, 2013. (Senior author, study design, manuscript preparation)
  114. Merkow RP, Bilimoria KY, Tomlinson JS, Paruch JL, Fleming JB, Talamonti MS, Ko CY, Bentrem DJ. Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer. Ann Surg, 260(2): 372-379, 2013. (Co-author, manuscript preparation)
  115. In H, Bilimoria KY, Stewart AK, Wroblewski KE, Posner MC, Talamonti MS, Winchester DP. Cancer recurrence: an important but missing variable in national cancer registries. Ann Surg Oncol 2014 May;21(5):1520-9 (Co-author, manuscript preparation)
  116. Brown CS, Lapin B, Wang C, Goldstein JL, Linn JG, Denham W, Haggerty SP, Talamonti MS, Howington JA, Cabray J, Ujiki MB. Predicting regression of Barrett’s esophagus: results from a retrospective cohort of 1342 patients. Surg Endosc. 2014 Oct:28(10):2803-7. Doi: 10:1007/s0064-014-3548-0 PMID: 24789137  (Co-author, manuscript preparation)
  117. Baker MS, Sherman KL, Stocker SJ, Hayman AV, Bentrem DJ, Prinz RA, Talamonti MS. Using a modification of the Clavien-Dindo system accounting for readmissions and multiple interventions: defining quality for pancreaticoduodenectomy. J Surg Oncol. 2014  Sep 110(4): 400-6 (Senior author, study design, manuscript preparation) PMID: 24861871
  118. Sharpe SM, In H, Winchester DJ, Talamonti MS, Baker MS. Surgical resection provides an overall survival benefit for patients with small pancreatic neuroendocrine tumors. J Gastrointest Surg. 2015 Jan;19(1):117-23. Doi: 10.1007/s11605-014-2615-0. PMID 25155459. (Senior author, study design, manuscript preparation)
  119. Ginsburg M, Ferral H, Alonzo MJ, Talamonti MS. Percutaneous transhepatic placement of a stent-graft to treat delayed mesoportal hemorrhage after pancreaticoduodenectomy. World J Surg Oncol 2014 Oct 15;12:315. Doi 10.1186/1477-7819-12-315. PMID: 25315011 (Senior author, manuscript preparation)
  120. Sur MD, In H, Sharpe SM, Baker MS, Weichselbaum RR, Talamonti MS, Posner MC. Defining the benefit of adjuvant therapy following resection for intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2014 Jul;22(7):2209-17. Dec 5. PMID: 25476031 (Co-author, manuscript preparation)
  121. Cherenfant J, Talamonti MS, Hall CR, Thurow TA, Gage MK, Stocker SJ, Lapin B, Want E, Silverstein JC, Mangold K, Odeleye M, Kaul KL, Lambazi I, Gattuso P, Winchester DJ, Marsh RW, Roggin KK, Bentrem DJ, Baker MS, Prinz RA. Comparison of tumor markers for predicting outcomes after resection of nonfunctioning pancreatic neuroendocrine tumors. Surgery. Dec: 156(6):1504-11. Doi: 10.1016/j.surg.2014.08.042 PMID: 25456943. (Senior author, study design, manuscript preparation)
  122. Brown CS, Lapin B, Wang C, Goldstein JL, Linn JG, Denham W, Haggerty SP, Talamonti MS, Howington JA, Cabray J, Ujiki MB. Reflux control is important in management of Barrett’s Esophagus: results from a retrospective 1,830 patient cohort. Surg Endosc. 2015 Feb. 13. PMID: 25676204. (Co-author, manuscript preparation)
  123. Liu JB, Meiselman MS, Talamonti MS. Interval asymptomatic infected postpancreatic resection fluid collections managed with endoscopic ultrasound-guided drainage. Am Surg. 2015 Apr; 18(4):146-7. PMID: 25831160. (Senior author, study design, manuscript preparation)
  124. Vigneswaran Y, Linn JG, Gitelis M, Muldoon JP, Lapin B, Denham W, Talamonti MS, Ujiki MB. Educating surgeons may allow for reduced intraoperative costs for inguinal herniorrhaphy. J Am Coll Surg. 2015 Mar 14. Pii: S1072-7515(15)0018-X. doi. 10.1016 PMID: 25868411 (Senior author, study design, manuscript preparation)
  125. Sharpe SM, Talamonti MS, Wang E, Bentrem DJ, Roggin KK, Prinz RA, Marsh RD, Stocker SJ, Winchester DJ, Baker MS. The laparoscopic approach to distal pancreatectomy for ductal adenocarcinoma results in shorter lengths of stay without compromising oncologic outcomes. Am J Surg. Mar; 209(3):557-63. 2015. Doi: 10.1016/j.amjsurg.2014.11.001. PMID 25596756. (Co-author, manuscript preparation)
  126. Gitelis M, Vigneswaran Y, Ujiki MB, Denham W, Talamonti MS, Muldoon JP, Linn JG. Educating surgeons on intraoperative disposable supply costs during laparoscopic cholecystectomy: a regional health system’s experience. Am J Surg. 2015 Mar:209(3):488-92. Doi: 10.106/j.amjsurg.2014.09.023. PMID: 25586597 (Co-author, manuscript preparation)
  127. Sharpe SM, Talamonti MS, Wang CE, Prinz RA, Roggin KK, Bentrem DJ, Winchester DJ, Marsh RD, Stocker SJ, Baker MS. Early national experience with laparoscopic pancreaticoduodenectomy for ductal adenocarcinoma: a comparison of laparoscopic pancreaticoduodenectomy and open pancreaticoduodenectomy from the National Cancer Data Base. J Am Coll Surg. 2015 Jul;221(1):175-84. Doi: 10.1016/j.jamcollsurg.2015.04.021. PMID: 26095569. (Senior author, study design, manuscript preparation)
  128. Moffitt RA, Marayati R, Flate EL, Volmar KE, Loeza SG, Hoadley KA, Rashid NU, Wiliams LA, Eaton SC, Chung AH, Smyla JK, Anderson JM, Bentrem DJ, Talamonti MS, Iacobuzio-Donahue CA, Hollingsworth MA, Yeh, JJ. Virtual microdissection identifies distinct tumor- and stroma- specific subtypes of pancreatic ductal adenocarcinoma. Nat Genet. 2015 Oct:47(10):1168-78. Doi: 10.1038?ng.3398. PMID: 26343385 (Co-author, manuscript preparation)
  129. Kantor O, Talamonti MS, Stocker SJ, Wang CH, Winchester DJ, Bentrem DJ, Prinz RA, Baker MS. A graded evaluation of outcomes following pancreaticoduodenectomy with major vascular resection in pancreatic cancer. J Gastrointest Surg. 2016 Feb;20(2):284-92 PMID: 26493974 (Senior author, study design, manuscript preparation)
  130. In H, Kantor O, Sharpe SM, Baker MS, Talamonti MS, Posner MC. Adjuvant therapy improves survival for T2N0 gastric cancer patients with suboptimal Lymphadenectomy. Ann Surg Oncol. 2016 Jun:23(6):1956-62. Doi: 10.1245/s10434-015-5075-1. . PMID: 26753752 (Senior author, study design, manuscript preparation)
  131. Katz MH, Shi Q, Ahmad SA, Herman JM, Marsh RW, Collisson E, Schwartz L, Frankel W, Martin R, Conway W, Trudy M, Kindler H, Lowy AM, Bekaii-Saab T, Philip P, Talamonti M, Cardin D, LoConte N, Shen P, Hoffman JP, Venook AP. Preoperative modified FOLFIRINOX treatment followed by capecitabine-based chemoradiation for borderline resectable pancreatic cancer: Alliance for Clinical Trials in Oncology Trial A021101. JAMA Surg. 2016 Aug 17; 151(8):e161137. Doi: 10.1001/jamasurg.2016.1137. PMID: 27275632 (Senior author, study design, manuscript preparation)
  132. Zureikat AH, Postlewait LM, Liu y, Gillespie TW, Weber SM, Abbott DE, Ahmad SA, Maithel SK, Hogg ME, Zenati M, Cho CS, Salem A, Xia B, Steve J, Nguyen TK, Keshava HB, Chalikonda S, Walsh RM, Talamonti MS, Stocker SJ, Bentrem DJ, Lumpkin S, Kim HJ, Zeh HH 3rd, Kooby DA. A multi-institutional comparison of perioperative outcomes of robotic and open pancreaticoduodenectomy. Ann Surg. 2016 Oct:264(4):640-9. Doi: 10.1097/SLA00000000001869. PMID: 27433907 (Co-author, manuscript preparation)
  133. Lutfi W, Talamonti MS, Kantor O, Wang CH, Liederbach E, Stocker SJ, Bentrem DJ, Roggin KK, Winchester DJ, Marsh R, Prinz RA, Baker MS. Perioperative chemotherapy is associated with a survival advantage in early stage adenocarcinoma of the pancreatic head. Surgery. 2016 Sep; 160(3):714-24. Doi: 10.1016/j. surg.2016.05.029. PMID: 27422328 (Senior author, study design, manuscript preparation)
  134. Kantor O, Talamonti MS, Stocker SJ, Wang CH, Winchester DJ, Bentrem DJ, Prinz RA, Baker MS. External radiation is associated with limited improvement in overall survival in resected margin-negative stage IIB pancreatic carcinoma. Surgery 2016 Dec; 160(6):1466-1476. Doi: 10.1016/j.surg.2016.07.033 PMID: 27614417 (Senior author, study design, manuscript preparation)
  135. Kantor O, Talamonti MS, Sharpe S, Lutfi W, Winchester DJ, Roggin KK, Bentrem DJ, Prinz RA, Baker MS. Laparoscopic pancreaticoduodenectomy for adenocarcinoma provides short-term oncologic outcomes and long-term overall survival rates similar to those for open pancreaticoduodenectomy. Am J Surg. 2017 Mar:213(3):512-515. Doi: 10.1016/jamasurg.2016.10.030. PMID 28049562 (Senior author, study design, manuscript preparation)
  136. Lutfi W, Talamonti MS, Kantor O, Wang CH, Stocker SJ, Bentrem DJ, Roggin KK, Winchester DJ, Marsh R, Prinz RA, Baker MS. Neoadjuvant external beam radiation is associated with no benefit in overall survival for early stage pancreatic cancer. Am J Surg. 2017 Mar:213(3):521-525. Doi: 10.1016/j.amjsurg.201611.039. PMID: 28089341 (Senior author, study design, manuscript preparation)
  137. Conlon KC, de Rooij T, van Hilst J, Abu Hidal M, Fleshman J, Talamonti M, Vanounou T, Garfinkle R, Velanovich V, Kooby D, Vollmer CM; Minimally Invasive Pancreatic Resections: cost and value perspectives. HPB (oxford). 2017 Mar 4. 19(3):225-233. Doi: 10.1016/j.hpb.2017.01.019. PMID: 28268161. (Co-author, manuscript preparation)
  138. Brown CS, Lapin B, Goldstein JL, Linn JG, Talamonti MS, Carbray J, Ujiki MB. Predicting progression in Barrett’s Esophagus: development and validation of the Barrett’s Esophagus Assessment of Risk Score (BEAR Score). Ann Surg. 2018 Apr;267(4):716-720. Doi: 10.1097/SLA.000000000002179. PMID: 28230661. (Senior author, study design, manuscript preparation)
  139. Vigneswaran Y, Poli E, Talamonti MS, Haggerty SP, Linn JG, Ujiki MB. Rectus abdominis atrophy after ventral abdominal incisions: midline versus chevron. Hernia. 2017 Aug;21(4):619-622. Doi: 10.1007/s10029-017-1593-z PMID: 28343314 (Co-author, manuscript preparation)
  140. Kantor O, Talamonti MS, Pitt HA, Vollmer CM, Riall TS, Hall BL, Wang CH, Baker MS. Using the NSQIP pancreatic demonstration project to derive a modified fistula risk score for preoperative risk stratification in patients undergoing pancreaticoduodenectomy. J Am Coll Surg. 2017 May:224(5):816-825. Doi: 10.1016/ja,cpollsurg.2017.01.054. PMID 28408176. (Senior author, study design, manuscript preparation)
  141. Xia BT, Ahmad SA, Al Humaidi AH, Hanseman DJ, Ethun CG, Maithel SK, Kooby DA, Salem A, Cho CS, Weber SM, Stocker SJ, Talamonti MS, Bentrem DJ, Abbott DE. Time to initiation of adjuvant chemotherapy in pancreas cancer: a multi-institutional experience. Ann Surg Oncol. 2017. Sep;24(9):2770-2776. Doi: 10.1245/s10434-017-5918-z PMID: 28600732. (Co-author, manuscript preparation)
  142. Kantor O, Bryan DS, Talamonti MS, Lutfi W, Sharpe S, Winchester DJ, Prinz RA, Baker MS. Laparoscopic distal pancreatectomy for cancer provides oncologic outcomes and overall survival identical to open distal pancreatectomy. J Gastrointest Surg. 2017 Oct;21(10):1620-1625.  Doi: 10.1007/s11605-017-33506-y. PMID: 28766272. (Senior author, study design, manuscript preparation)
  143. Liu JB, Baker TB, Suss NR, Talamonti MS, Roggin KK, Winchester DJ, Baker MS. Orthotopic liver transplantation provides a survival advantage compared with resection in patients with hepatocellular carcinoma and preserved liver function. Surgery. 2017 Nov;162(5):1032-1039. Doi: 10.1016/j.surg 2107.07.017 PMID: 28866312. (Co-author, manuscript preparation)
  144. De W Marsh R, Talamonti MS, Baker MS, Posner M, Matthews J, Catenacci D, Kozloff M, Polite B, Britto M, Wang C, Kindler H. Primary systemic therapy in resectable pancreatic ductal adenocarcinoma using mFLOFIRINOX: a pilot study. J Surg Oncol. 2018 Mar;117(3):354-362. Doi: 10.1002/jso.24872. PMID: 29044544 (Senior author, study design, manuscript preparation)
  145. Kantor O, Talamonti MS, Wang CH, Roggin KK, Bentrem DJ, Winchester DJ, Prinz RA, Baker MS. The extent of vascular resection is associated with perioperative outcome in patients undergoing pancreaticoduodenectomy. HPB (Oxford). 2018 Feb;20(2):140-146.. Doi: 10.1016/j.hpb.2017.08.012. PMID: 29191690. (Senior author, study design, manuscript preparation)
  146. Namm JP, Thakrar KH, Wang CH, Stocker SJ, Sur MD, Berlin J, Dale W, Talamonti MS, Roggin KK. A semi-automated assessment of sarcopenia using psoas area and density predicts outcomes after pancreaticoduodenectomy for pancreatic malignancy. J Gastrointest Oncol. 2017 Dec:8(6):936-944. Doi: 10.21037/jgo.2017.08.09. PMID: 29299352. (Senior author, study design, manuscript preparation)
  147. Benjamin AJ, Baker TB, Talamonti MS, Bodzin AS, Schneider AB, Winchester DJ, Roggin KK, Bentrem DJ, Suss NR, Baker MS. Liver transplant offers a survival benefit over margin negative resection in patients with small unifocal hepatocellular carcinoma and preserved liver function. Surgery. Mar;163(3):582-586. Doi: 10.1016/j.surg.2017.12.005. PMID” 29370929. (Senior author, study design, manuscript preparation)
  148. Suss NR, Talamonti MS, Bryan DS, Wang CH, Kuchta KM, Stocker SJ, Bentrem DJ, Roggin KK, Winchester DJ, Marsh R, Prinz RA, Murad FM, Baker MS. Does adjuvant radiation provide any survival benefit after an R1 resection for pancreatic cancer? Surgery. 2018 May; 163(5):1047-1052. Doi: 10.1016/j.surge.2017.09.022. PMID: 29336810. (Senior author, study design, manuscript preparation)
  149. Kantor O, Pitt HA, Talamonti MS, Roggin KK, Bentrem DJ, Prinz RA, Baker MS. Minimally invasive pancreaticoduodenectomy: is the incidence of clinically relevant postoperative pancreatic fistula comparable to that after open pancreaticoduodenectomy? Surgery. 2018 Mar;163(3):587-593. Doi: 10.1016/j.surg.2017.12.001. PMID: 2945444 (Senior author, study design, manuscript preparation)
  150. Pitroda SP, Khodarev NN, Huang L, Uppal A, Wightman SC, Ganai S, Joseph N, Pitt J, Brown M, Forde M, Mangold K, Xue L, Weber C, Degal JP, Kadri S, stack ME, Khan S, Paty P, Kaul K, Andrade J, White KP, Talamonti MS, Posner MC, Hellman S, Weichselbaum RR. Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis.  Nat Commun. 2018 May 4;9(1):1793. Doi: 10.1007/s11605-017-3506-y PMID: 28766272 (Co-author, manuscript preparation)
  151. Innocenti F, Owzar K, Jian C, Etheridge AS, Gorday R, Sibley AB, mulkey F, Niedzwiecki D, Glubb D, Neel N, Talamonti MS, Bentrem DJ, Seiser E, Yeh JJ, Van Loon K, McLeod H, Raian MJ, Kindler HL, Venook Ap, Nakamura Y, Kubo M, Petersen GM, Bamlet Wr, McWilliams RR. The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation. PLos One. 2018 Agu 14;13(8):e0202272. Doi: 10.137/journal.pone.0202272 PMID: 30107003 (Co-author, manuscript preparation)
  152. Diaz Quintero LA, Fuentes HE, Tafur AJ, Majmudar K, Salazar Adum JP, Golemi I, Pas LH, Stocker S, Talamonti MS. Pancreatic cancer thromboembocolic outcomes: rate of thrombosis after adenocarcinoma and non-adenocarcinoma pancreatic cancer surgery. Int Angiol. 2019 Jun;38(3): 194-200. Doi: 10.23736/S0392-9590.19.04127-0. PMID: 31112026 (Senior author, study design, manuscript preparation)
  153. Majmudar K, Quintero LD, Fuentes HE, Stocker S, Tafur AJ, Lee CJ, Talamonti M. Postoperative venous thromboembolism and mortality in patients with pancreatic surgery. J Surg Oncol. 2019 Sep:123(3):494-500  10.1002/jso.25589. PMID: 31222842 (Co-author, manuscript preparation)
  154. Asbun HJ, Moekotte AL, Vissers FL, Talamonti MS, International Study Group on Minimally Invasive Pancreas Surgery (I-MIPS). The Miami International Evidence-based Guidelines on Minimally Invasive Pancreas Resection. Ann Surg. 2020 Jan;271(1);1-14. Doi: 10.1097/SLA.000000000003590. PMID: 31567509 (Co-author, manuscript preparation)
  155. Ellis RJ, Zhang LM, Ko CY, Cohen ME, Bentrem DJ, Yang AD, Talamonti MS, Merkow RP. Variation in hospital utilization of minimally invasive distal pancreatectomy for localized pancreatic neoplasms. J Gastrointest Surg. 2020 Dec;24(12):2780-2788. Doi: 10.1007/s11605-019-04414-7. PMID: 31768832
  156. Vining CC, Kuchta K, Schuitevoerder D, Paterakos P, Berger Y, Roggin KK, Talamonti MS, Hogg ME. Risk factors for complications in patients undergoing pancreaticoduodenectomy: A NSQIP analysis with propensity score matching. J Surg Oncol. 2020 Aug;122(2):183-194. Doi: 10.1002/jso.25942. PMID: 32445612.  (Co-author, study design, manuscript preparation)
  157. Vining CC, Eng OS, Hogg ME, Schuitevoerder D, Silverman RS, Yao KA, Winchester DJ, Roggin KK, Talamonti MS, Posner MC, Turao KK, Tseng J. Virtual surgical fellowship recruitment during COVID-19 and its implications for resident/fellow recruitment in the future.  Ann Surg Oncol. 2020 Dec;27(Suppl 3):911-915. Doi: 10.1245/s10434-020-08623-2. PMID: 32424589 (Co-author, manuscript preparation)
  158. Vining CC, Kuchta K, Berger Y, Paterakos P, Achuitevoerder D, Roggis KK, Talamonti MS, Hogg ME. Robotic pancreaticoduodenectomy decreases the risk of clinically relevant post-operative pancreatic fistula: a propensity score matched NSQIP analysis.  HPB. 2020 Aug 15:S1365-182X(20)31093-7. Doi: 10.1016/j.hpb.2020.07.004. PMID32811765. (Co-author, study design, manuscript preparation)
  159. Shi Z, Wei J, Na R, rsurreccion WK, Zheng SL, Hulick PJ, Helfand BT, Talamonti MS, Xu J. Cystic fibrosis F508del carriers and cancer risk: results from the UK Biobank.  Int J Cancer. 2020 Dec 10.  Doi: 10.1002/ijc.33431. PMID: 33300603

Invited Publications:

  1. Talamonti MS:  Management of ductal carcinoma in situ.  Semin Surg Oncol 12:300-313, 1996. (Senior author, manuscript preparation)
  2. Miller FH, Kochman MI, Talamonti MS, Ghahremani GG, Gore RM:  Gastric Cancer: Radiologic Staging.  Radiol Clin North Am 35(2):331-349, 1997. (Co-author, manuscript preparation)
  3. Brenin DR, Talamonti MS, Iannaccone PM.  Transgenic technology: An overview of approaches useful in surgical research. Surgical Oncology 6:99-110, 1997.  (First faculty author, mentor, manuscript preparation)
  4. Klimberg VS, Galandiuk S, Singletary ES, Cohen A, Sener S, Talamonti MS, Witt TR, Niederhuber JE, Edwards MJ.  Society of Surgical Oncology: Statement on genetic testing for cancer susceptibility.  Ann Surg Onc 6:507-510, 1999. (Co-author, manuscript review)
  5. Talamonti MS, Denham EW, Staging and surgical management of pancreatic and biliary cancer and inflammation. Ed. F. Miller, Rad Clin of N Amer 40: 1397-1410, 2002. (Primary author, manuscript preparation)
  6. Ujiki MB, Talamonti MS. Surgical Management of Pancreatic Cancer. Semin Radiat Oncol 15:218-225, 2005. (Senior author, mentor, manuscript preparation)
  7. Talamonti MS.  Borderline Resectable Pancreatic Cancer: A New Classification for an Old Challenge. Ann Surg Oncol 13(8):1019-1020, 2006. (Invited editorial)
  8. Ujiki MB, Talamonti MS. Guidelines for the Surgical Management of Pancreatic Adenocarcinoma.  Semin Oncol Aug 34(4): 311-320, 2007. (Senior author, mentor, manuscript preparation)
  9. Talamonti, MS.  Endoscopic ultrasound for gastric cancer: a technique for preoperative risk stratification in need of further refinements.  Ann Surg Oncol 12: 3293-3294, 2007. (Invited editorial)
  10. Callery MP, Chang KJ, Fishman EK, Talamonti MS, Traverson W, Linehan DC. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement.  Ann Surg Oncol, Jul; 16(7): 1727-33, 2009.
  11. Raval MV, Bilimoria KY, Talamonti MS.  Quality Improvement for Pancreatic Cancer: Is Regionalization a Feasible and Effective Mechanism?  Surg Onc Clin N Amer, 19: 371-390, 2010. (Senior author, mentor, manuscript preparation)
  12. Abbott DE, Baker MS, Talamonti MS. Neoadjuvant therapy for pancreatic cancer: a current review.  J Surg Oncol.  March 15; 101(4): 315-320, 2010.  (Senior author, mentor, manuscript preparation)
  13. Cheon EC, Small W, Strouch MJ, Krantz SB, Rademaker A, Mulchay MF, Benson AB, Bentrem DJ, Talamonti MS.  The effects of bevacizumab on postoperative complications in patients undergoing colorectal and pancreatic cancer resection.  J Surg Oncol. 102(5): 539-542, 2010. (Senior author, mentor, manuscript preparation)
  14. Marsh RDW, Alonzo M, Bajaj S, Baker M, Elton E, Farrell TA, Gore RM, Hall C, Nowak J, Roy H, Shaikh A, Talamonti MS. Comprehensive Review of the Diagnosis and Treatment Of Biliary Tract Cancer 2012. PART I: Diagnosis-Clinical Staging and Pathology. J Surg Onc. 106(3): 332-338, 2012. (Senior author, mentor, manuscript preparation)
  15. Marsh RDW, Alonzo M, Bajaj S, Baker M, Elton E, Farrell TA, Gore RM, Hall C, Nowak J, Roy H, Shaikh A, Talamonti MS. Comprehensive Review of the Diagnosis and Treatment of Biliary Tract Cancer 2012. PART II: Multidisciplinary Management. J Surg Onc. 106(3): 339-345, 2012.  (Senior author, mentor, manuscript preparation)
  16. Marsh RW, Talamonti MS, Katz MH, Herman JM. Pancreatic cancer and FOLFIRINOX: a new era and new questions. Cancer Med. 2015 Jun;4(6):853-63. Feb 19. Doi: 10.1002/cam4.433. PMID: 25693729. (Co-author, manuscript review)
  17. Talamonti MS. Screening strategies for pancreatic cancer in high-risk patients: opportunities to make a real impact but many questions and challenges still ahead. JAMA Surg. 2015 Jun:150(6):518-9. Doi: 10.1001/jamasurg.2015.0391 PMID: 25853232 (Invited commentary, manuscript preparation)
  18. Baker MS, Sharpe SM, Talamonti MS, Wsang E, Roggin KK, Bentrem DJ, Winchester DJ, Marsh RS, Stocker SJ. The learning curve is surmountable: in reply to Fong and colleagues. J Am Coll Surg. 2016 Feb; 222(2):210-1. Doi: 10.1016/j.jamcollsurg.2015.11.005 PMID: 26809388 (Co-author, response review)
  19. Gore RM, Pickhardt PJ, Mortele KJ, Fishman EK, Horowitz JM, Fimmel CJ, Talamonti MS, Berland LL, Pandharipande PV.. Management of incidental liver lesions on CT: a white paper of the American College of Radiology Incidental Findings Committee. J Am Coll Radiol. 2017 Nov;14(11):1429-1437. Doi: 10.1016/j.jacr.2017.07.018. PMID: 28927870 (Co-author, manuscript review)
  20. Talamonti MS. Impact, Insight, and Innovation: Our Legacy of Learning. Presidential Address of the Western Surgical Association. J Am Coll Surg. 2019 Jul;229(1):1-6. Pii: S1072-751(19)30150-4. Doi: 10.1016/j.amcollsurg.2019.02.041. PMID: 30794863 (Author, Presidential Address)

Books:

  1. Liver-directed Therapy for Primary and Metastatic Hepatic Malignancies. Editor: Mark S. Talamonti, MD. Kluwer Medical Publishers, Boston, 2002.
  2. Gastrointestinal Oncology. Editors: Charles Blanke, Claude Rodel, Mark S. Talamonti, MD. Springer Publishers, Germany, 2011.

Book Chapters:

  1. Gallick GE, Talamonti MS, Nicolson GL:  Proto-oncogenes and tumor suppressor genes in endocrine tumors.  In:  Endocrine Tumors.  Eds:  Mazzaferi/Samaan, Blackwell Scientific Publications, Inc., Boston, MA  1993.
  2. Pellis NR, Byrd DL, Talamonti MS, Balch CM:  Oncology.  In:  Scientific Principles and Practice in Surgery.  Eds:  Greenfield, Mulholland, Oldham, Zelenock.  J. B. Lippincott Publishers, Inc. 1993.
  3. Talamonti MS, Curley SA, Gallick GE:  Current concepts in the development and progression of human colon cancer.  In:  Cancer Bulletin 44(4):321-326, 1992.
  4. Talamonti MS:  Diagnosis of the Palpable Breast Mass.  ACS Postgraduate Course on Breast Surgery.  Annual Clinical Congress of the American College of Surgeons, 1994.
  5. Talamonti MS, Lyster M, Benson AB:  The Carcinoid Syndrome:  Carcinoid of the ileum with liver metastases.  In:  Tumor Board:  Case Management.  Eds.  Winchester, Brennan, Dodd, Henson, Kennedy, Steele, and Wilson.  J.B. Lippincott Publishers, Inc. 1996.
  6. Von Gunten CF, Von Roenn JH, Talamonti MS, Mittal B:  HIV-Associated Anal Cancer.  In:  Tumor Board:  Case Management.  Eds. Winchester, Brennan, Dodd, Henson, Kennedy, Steele, and Wilson.  J.B. Lippincott Publishers, Inc. 1996.
  7. Talamonti MS and Morrow M:  Workup of the Abnormal Screening Mammogram.  In:  Diseases of the Breast.  Harris J, Lippman M, Morrow M, Hellman S (eds)  Lippincott-Raven, Philadelphia, p. 114-121, 1996.
  8. Talamonti MS.  Hepatic Artery Infusion and Cryotherapy.  American College of Surgeons Annual Clinical Congress, Postgraduate Course:  Advances and Controversies in the Management of Colon Cancer, Breast Cancer, Melanoma and Sarcoma: 15-18, 1997.
  9. Talamonti MS. Surgical Strategy in the Laparoscopic Staging and Treatment of Gastric Neoplasms. American College of Surgeons Annual Clinical Congress, Postgraduate Course: Minimal Access Surgery,1-4, 1997.
  10. Talamonti MS.  Gastric Cancer.  In:  Cancer Surgery for the General Surgeon.  Eds. Winchester DP, Daly JM, Jones RS, and Murphy GP.  Lippincott-Raven, Philadelphia, p. 173-194, 1998.
  11. Talamonti MS.  Locoregional Therapies for Metastatic Liver Tumors.  In: Gastrointestinal Oncology.  Eds.  Benson AB and Rosen SR.  Kluwer Medical Publishers,  p. 175-196, 1998.
  12. Miller FM, Gabriel H, Talamonti MS, Nahrwold DL.  Pancreatic Trauma and Surgery.  In: Textbook of Gastrointestinal Radiology. 2nd Edition, Eds. Gore RM and Levine MS. Saunders, Philadelphia, p. 1812-1823, 2000.
  13. Miller FM, Gabriel H, Talamonti MS, Nahrwold DL.  Hepatic Trauma and Surgery.  In: Textbook of Gastrointestinal Radiology. 2nd Edition, Eds. Gore RM and Levine MS. Saunders, Philadelphia, p. 1669-1688, 2000.
  14. Talamonti MS. Management of the Discrete Liver Metastasis. In: Diseases of the Breast.  Harris J, Lippman M, Morrow M, Hellman S (eds)  Lippincott-Raven, Philadelphia, p. 907-910, 2000.
  15. Bimstom D. and Talamonti MS.  Malignant Melanoma.  In: Northwestern Handbook of Oncology.  Rosen S and Kuzel T (eds). PRR, Melville, New York.  p. 320-335, 2001.
  16. Bimstom D. and Talamonti MS.  Adult Soft Tissue Sarcoma. In: Northwestern Handbook of Oncology.  Rosen S and Kuzel T (eds). PRR, Melville, New York.  p. 307-319, 2001.
  17. Danekar GS and Talamonti MS.  Cancers of the Liver.  In: Oxford Textbook of Surgery.  Oxford University Press, New York, p. 1631-1652, 2001.  
  18. Talamonti MS and Murayama KM. Laparoscopic Colon Resection.  In: Current Surgical Therapy.  Cameron J (editor).  Mosby, St. Louis, p.1404-1411, 2001.
  19. Talamonti MS.  “Endoscopic Ultrasound in the Diagnosis and Staging of Pancreatic Neoplasms.”  Editorial Review and Comment. Oncology 16:54-6, 2001.
  20. Talamonti MS. Glucagonoma. In: Surgical Oncology: An Algorithmic Approach.  1st Edition, Eds. Saclarides T, Millikan K, and Godellas C.  Springer-Verlag,  New York, p. 114-119, 2003.
  21. Small WS, Talamonti MS, and Benson AB. Clinical Aspects and Management of Esophageal Carcinoma: Management Options: Locally Advanced Unresectable Esophageal Cancer.  In: The Principles and Practice of Gastrointestinal Oncology.  Abbruzzese, Evans, Willett, and Hamilton (eds.)  Oxford University Press, New York. Chapter 17, 218-226, 2004
  22. Talamonti MS. Management of Isolated Liver Metastases. In: Diseases of the Breast. Harris J, Lippman M, Morrow M, Osborne K. (eds) Lippincott, Williams & Wilkins, Baltimore, 3rd edition Chapter 80, 1279-1283, 2004
  23. Talamonti MS and Wayne JD.  Tumors of the Stomach, Duodenum, and Small Bowel. In: American College of Surgeons: Principles and Practice of Surgery. Eds. Souba WW, Fink MP, Jurkovich GJ, Kaiser LR, Pearce WH, Pemberton JH, Soper NJ. WebMD Inc. Section 5 Gastrointestinal Tract and Abdomen, Chapter 8, 1-13 New York, 2005
  24. Talamonti MS and Bentrem DJ.  Surgical Treatment of Gastroesophageal Junction Adenocarcinoma.  In: Advanced Therapy in Surgical Oncology.  Eds. Curley S, Ross M, Perrier N, and Pollack R.  BC Decker, Inc. Hamilton, 41-51, 2008.
  25. Miller FM, Gabriel H, Talamonti MS.  Pancreatic Trauma and Surgery.  In: Textbook of Gastrointestinal Radiology. 3rd Edition, Eds. Gore RM and Levine MS.  WB Saunders, Philadelphia p. 1933-1948, 2008.
  26. Miller FM, Gabriel H, Talamonti MS.  Hepatic Trauma and Surgery.  In: Textbook of Gastrointestinal Radiology. 3rd Edition, Eds. Gore RM and Levine MS. WB Saunders, Philadelphia, p. 1771-1794, 2008.
  27. Bilimoria KY, Talamonti MS, Wayne JD.  Tumors of the Stomach, Duodenum, and Small Bowel. In: American College of Surgeons: Principles and Practice of Surgery. Eds. Souba WW, Fink MP, Jurkovich GJ, Kaiser LR, Pearce WH, Pemberton JH, Soper NJ. WebMD Inc. Section 5 Gastrointestinal Tract and Abdomen, Chapter 8, New York, 2010.
  28. Sharpe SM and Talamonti MS. Neoadjuvant Therapy for Borderline Resectable Pancreatic Head Cancer. In: Difficult Decisions in Hepatobiliary and Pancreatic Surgery: An Evidence-Based Approach p. 567-583. Eds. Matthews JB and Millis JM. Springer, Switzerland, 2016.
  29. Talamonti MS. Management Controversies and Treatment Strategies for Borderline Resectable Pancreatic Cancer. In: Current Therapy of Hepatobiliary and Pancreatic Cancers. p. 59-77. Eds. Benson AB and Bentrem DJ, Switzerland, 2016.
  30. Talamonti MS. Pancreaticojejunostomy: How I Do It. CSurgeries – Web based Surgical Videos.  Section Ed. Matthews JB. www.csurgeries.com, http://www.csurgeries.com/video/two-layered-end-to-side-duct-to-mucosa-pancreaticojejunostomy/wvi4b33r6r

Editorial Responsibilities and Committees

Editorial Board:

Annals of Surgical Oncology
Journal of Surgical Oncology
Section Editor, Hepatobiliary and Pancreas      

Invited Reviewer:    

American Journal of Surgery
Annals of Surgery
Archives of Surgery
Cancer
Journal of the American College of Surgeons
Journal of Clinical Oncology
Oncology
Surgery
World Journal of Surgery                                  

Presentations:

  1. “Results of Resection of Hepatocellular Carcinoma,” Current Mechanisms of Colorectal Tumorigenesis and Progression to Metastatic Liver Disease”  Update on Liver Surgery for Hepatocellular Carcinoma and Colorectal Metastases, National Cancer Institute of Italy, Naples, Italy, 6/22-23/91.  Presenter.
  2. “Cancer:  A Women’s Issue.”  Surgical Issues in the Treatment of Primary Cancer, The Chicago Maternity Center, Health Issues for Women, Chicago, 10/21/92.  Presenter.
  3. “Current Management of Early Stage Breast Cancer.” Lynn Sage Breast Cancer Foundation, Chicago, 5/1/93.  Presenter.
  4. “Metabolism of Metastatic Liver Tumors.”  Chicago Surgical Society, Chicago, 3/12/93.   Discussant.
  5. “The Biologic Progression of Colorectal Cancer to Metastatic Disease.”  McGaw Medical Center, Surgical Grand Rounds, Chicago, IL, 4/3/93.  Presenter.
  6. “Current Issues in the Management of Pancreatic Cancer.”  St. Margaret Mercy Health Care Center, Dyer, IN, 5/5/93.  Presenter.
  7. "Pros and Cons of Current Pancreatic Cancer Protocols,” Northwestern University Medical School, Surgical Grand Rounds, Chicago, IL 3/29/94. Presenter.
  8. “Diagnosis of the Palpable Breast Mass.”  American College of Surgeons, 80th Clinical Congress, Postgraduate Course on Breast Surgery, Chicago, 10/16/94. Presenter.
  9. “Cystic Pancreatic Neoplasms.” Chicago Surgical Society, Chicago, IL  2/2/95. Presenter.
  10. “Advances in the Surgical Management of Gastrointestinal Cancers.”  Malnati Symposium, Chicago, IL  6/15/95.  Presenter.
  11. “Current Management of Colorectal Cancer.”  Malnati Symposium, Chicago, IL  10/5/95.   Presenter.
  12. “Endothelial Cell Invasion is Enhanced by the Urokinase-type Plasminogen Activator System in Colon Cancer Cell Lines.”  Surgical Forum, American College of Surgeons, New Orleans, La. 10/10/95.  Presenter.
  13. “Doctor-Patient Relationships.”  Wellness House, Chicago, IL 11/30/95 Presenter.
  14. “Principles of Surgical Oncology.”  The National Center for Advanced Medical Education, Specialty Review in General Surgery, Chicago, IL 1/17/96. Instructor.
  15. “Management of Benign and Malignant Breast Disease” The National Center for Advanced Medical Education, Specialty Review in General Surgery, Chicago, IL, 1/17/96.   Instructor.
  16. “Laparoscopic Colectomy.”  Chicago Medical Society Midwest Clinical Conference, Chicago, IL, 1/20/96.  Presenter.
  17. “Breast Cancer.”  Southwestern Surgical Conference, Scottsdale, AZ, 4/28/96, 1996.
  18. “Current Multi-Modality Trials for Pancreatic Cancer.”  Eastern Cooperative Oncology Group Spring Meetings, Baltimore, MD, 3/3/96.  Presenter.
  19. “Soft Tissue Sarcomas.”  The National Center for Advanced Medical Education, Specialty Review in General Surgery, Part 1, Chicago, IL, 8/16/96.  Instructor.
  20. ”Melanoma and Other Surgical Skin Lesions; Tumor Markers.”  The National Center for Advanced Medical Education, Specialty Review in General Surgery, Part 1, Chicago, IL, 8/16/96.  Instructor.
  21. “Surgical Skin Lesions.”  The National Center for Advanced Medical Education, Specialty Review in General Surgery, Part 1, Chicago, IL  9/12/96.  Instructor.
  22. “Soft Tissue Sarcomas.”  The National Center for Advanced Medical Education, Specialty Review in General Surgery, Part 1, Chicago, IL  9/12/96.  Instructor.
  23. “Basic Research and Clinical Trials for Pancreatic Cancer.”  McGaw Medical Center Integrated Surgical Grand Rounds, Chicago, IL  3/1/97.  Presenter.
  24. “Clinical Management of Esophageal Carcinoma.”  Northwestern University Medical School, Division of Cardiothoracic Surgery, Chicago, IL  3/19/97. Presenter.
  25. “Advances in the Treatment of Colorectal Cancer and Its Metastases.”  Northwestern Memorial Hospital Outreach CME Program, at St. Anthony Medical Center, Crown Point, IN 5/22/97.  Presenter
  26. “Principles of Surgical Oncology.” The National Center for Advanced Medical Education, Specialty Review in General Surgery, Part 1, Chicago, IL  8/22/97. Instructor
  27. “Benign and Malignant Breast Diseases.”  The National Center for Advanced Medical Education, Specialty Review in General Surgery, Part 1, Chicago, IL  8/23/97.  Instructor
  28. “Hepatic Artery Infusion and Cryotherapy.”  American College of Surgeons Annual Clinical Congress, Postgraduate Course:  Advances and Controversies in the Management of Colon Cancer, Breast Cancer, Melanoma and Sarcoma.  Session 1 - Colon and Rectal Cancer, Chicago, IL 10/13/97.  Instructor.
  29. “Surgical Strategy in the Laparoscopic Staging and Treatment of Gastric Neoplasms.” American College of Surgeons Annual Clinical Congress, Postgraduate Course: Minimal Access Surgery, Chicago, IL 10/13/97. Instructor.
  30. “Principles of Surgical Oncology.”  The National Center for Advanced Medical Education, Specialty Review in General Surgery, Part 1, Chicago, IL  1/13/98. Instructor
  31. “Benign and Malignant Breast Diseases.”  The National Center for Advanced Medical Education, Specialty Review in General Surgery, Part 1, Chicago, IL  1/13/98. Instructor
  32. “Surgical Skin Lesions.”  The National Center for Advanced Medical Education, Specialty Review in General Surgery, Part 1, Chicago, IL  1/12/98.  Instructor.
  33. “Soft Tissue Sarcomas.”  The National Center for Advanced Medical Education, Specialty Review in General Surgery, Part 1, Chicago, IL  1/12/98.  Instructor.
  34. “Primary Gastrointestinal Sarcomas: Analysis of Prognostic Factors and Results of Surgical Management.”  Chicago Surgical Society 2/5/98.  Presenter.
  35. “NuMA: Evaluation of a New Biomarker for the Detection of Low Stage Colorectal Cancer.”  The Fourth Joint Conference of the American Association for Cancer Research and the Japanese Cancer Association:  Innovative Approaches to the Prevention, Diagnosis, and Therapy of Cancer. Maui, Hawaii 2/16/98.  Poster
  36. “Benign and Malignant Breast Diseases.”  The National Center for Advanced Medical Education, Specialty Review in General Surgery, Part 1, Chicago, IL  1/13/98. Instructor
  37. “Surgical Skin Lesions.”  The National Center for Advanced Medical Education, Specialty Review in General Surgery, Part 1, Chicago, IL  1/12/98.  Instructor.
  38. “Soft Tissue Sarcomas.”  The National Center for Advanced Medical Education, Specialty Review in General Surgery, Part 1, Chicago, IL  1/12/98.  Instructor.
  39. “Primary Gastrointestinal Sarcomas: Analysis of Prognostic Factors and Results of Surgical Management.”  Chicago Surgical Society 2/5/98.  Presenter.
  40.  “State of The Art Management of Pancreatic Cancer.”  Lurie Cancer Center Annual Symposium on Gastrointestinal Oncology.  Symposium Chairman, 9/18/98
  41. “Benign and Malignant Breast Diseases.”  The National Center for Advanced Medical Education, Specialty Review in General Surgery, Part 1, Chicago, IL  2/15/99.  Instructor
  42. “Surgical Skin Lesions.”  The National Center for Advanced Medical Education, Specialty Review in General Surgery, Part 1, Chicago, IL  2/15/99.  Instructor.
  43. “Soft Tissue Sarcomas.”  The National Center for Advanced Medical Education, Specialty Review in General Surgery, Part 1, Chicago, IL  2/15/99.  Instructor.
  44. “Results of Gastric Interposition for Reconstruction of the Pharyngoesophagus.”  Central Surgical Association, St. Louis, Mo.  3/5/99.  Presenter.
  45. “Current Management of Esophageal Cancer, Meet the Professor Breakfast Session.”  Society of Surgical Oncology, Orlando, FL.  3/6/99.  Presenter.
  46. “Management of the Patient with Hereditary Nonpolyposis Colon Cancer.”   Society of Surgical Oncology, Orlando, FL.  3/7/99.  Presenter.
  47. “Surgical Management of Colorectal Cancer: Role of Sentinel Lymph Node Biopsy.” National Cancer Cooperative Groups, Internet Web Broadcast, 10/18/99.  Presenter.
  48. “Results of Surgical Management and Analysis of Prognostic Factors of Primary Gastrointestinal Sarcomas.”  Central Surgical Association, Chicago, Illinois.  3/3/00.  Presented by Katharine Yao, Surgical Resident, (Faculty Advisor).
  49. “The Medical Ethics of Randomized Clinical Trials.”  Society of Surgical Oncology, New Orleans, Louisiana.  3/17/00.  Moderator and Presenter of Symposium and Discussion Session.
  50. “Liver-Directed Therapy for Primary Hepatocellular Cancer & Secondary Liver Tumors.”  Northwestern University Medical School and the Robert H. Lurie Comprehensive Cancer Center, Chicago, 4/28/00. Course Director.
  51. “Indications and Results of Surgical Resection for Metastatic Liver Tumors.”  Northwestern University Medical School and the Robert H. Lurie Comprehensive Cancer Center, Chicago, 4/28/00. Presenter.
  52. “Surgical Strategy in the Laparoscopic Staging and Treatment of Upper Gastrointestinal Neoplasms.” Eastern Cooperative Oncology Group National Meeting, Pittsburgh, PA., 6/3/00.  Presenter.
  53. “Indications and Results of Hepatic Resection and Chemoembolization for Metastatic Gastrointestinal Neuroendocrine Tumors.”  Central Surgical Association, Tucson, Arizona.  3/9/01.  Presented by Katharine Yao, Surgical Resident, (Faculty Advisor).
  54. “Primary Small Bowel Cancers:  Analysis of Prognostic Factors and Results of Surgical Management.”  Western Surgical Association, San Antonio, Texas.  11/14/01.  Presenter.
  55. “Current Management of Gastric Cancer.”  Illinois Surgical Society, Chicago, Illinois.  5/6/01. Presenter.
  56. “Results of Palliative Resections for Stage IV Colorectal Cancer.”  Western Surgical Association, Vancouver, BC.  11/17/02. Presenter.
  57. “Surgical Outcomes of Gastric Carcinoma Patients: The Importance of Primary Tumor Location and Vessel Invasion.”  Central Surgical Association, Toronto, Canada.  3/22/03.  Presenter.
  58. “Combined Modality Treatment for Pancreatic Cancer.” Northwestern University’s Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center Annual Clinical Science Symposium. Chicago, 6/13-14/03, Moderator and Presenter.
  59. “Surgical Issues in the Treatment of Pancreatic Cancer.” New Mexico Surgical Society, Albuquerque, New Mexico. 12/18/03.  Invited Guest Speaker.
  60. “Neuroendocrine Tumors of the Gastrointestinal Tract: How Aggressive Should We Be?”  American Society of Clinical Oncology (ASCO).  New Orleans, Louisiana. 6/5 and 6/7/04. Moderator and Presenter.
  61. “Surgical Management Issues for Localized Pancreatic Cancer.”  American Pancreatic Association, Post-Graduate Course.  Chicago, Illinois.  11/6/04. Invited Panel Member.
  62. “Doctor, Lend Me Your Ear: A Look at the Doctor-Patient Relationship.”  Pancreatic Cancer Symposium.  Pancreatic Cancer Action Network (PanCAN).  Los Angeles, California.  11/12/04.  Invited Speaker.
  63. “Surgical Approaches to Proximal Esophageal Cancer.”  MD Anderson Cancer Center Symposium on Multidisciplinary Management of Gastrointestinal Malignancies.  Kauai, Hawaii.  11/14/04.  Invited Speaker.
  64. “Surgical Options for Gastroesophageal Junction Cancer.”  MD Anderson Cancer Center Symposium on Multidisciplinary Management of Gastrointestinal Malignancies.  Kauai, Hawaii.  11/14/04.  Invited Speaker.
  65. "Increasing Survival Rates for Pancreatic Cancer – New Treatment Options.”  United Resource Networks (URN) Cancer Symposium.  Miami, Florida.  3/2/05. Invited Speaker.
  66. “A Multi-Institutional Phase II Trial of Preoperative Full Dose Gemcitabine and Concurrent Radiation for Patients with Potentially Resectable Pancreatic Cancer.”  Society of Surgical Oncology.  Atlanta, Georgia.  3/4/05.  Presenter.
  67. “Pre-operative Evaluation of Pancreatic Cystic Lesions: Cost Benefit Analysis and Proposed Management Algorithm.”  Central Surgical Association.  Tucson, Arizona.  3/11/05.  Presented by Sherry Lim, Surgical Resident, (Faculty Advisor).
  68. “A Prospective Randomized Trial Comparing Standard Pancreaticoduodenectomy with Pancreaticoduodenectomy and Extended Lymphadenectomy in Resectable Pancreatic Head Adenocarcinoma” Central Surgical Association.  Tucson, Arizona. 3/11/05.  Invited Discussant.
  69. “Doctor, Lend Me Your Ear: A Look at the Doctor-Patient Relationship.”  Pancreatic Cancer Symposium.  Pancreatic Cancer Action Network (PanCAN).  Chicago, Illinois.  4/8/05.  Invited Speaker.
  70. “Assessing the outcomes for treatment of difficult diseases, potential pitfalls of nadequate staging systems, variations in supposedly standardized procedures and the impact of novel therapies on quality of life in advanced cancers.”  American Society of Clinical Oncology (ASCO). Orlando, Florida.  5/20/05.  Invited Discussant, Gastrointestinal Plenary Session.
  71. “Sarcoma Liver Metastasis: Is Surgical Resection or Ablation Justified?” Western Surgical Association. Rancho Mirage, California. 11/8/05. Invited Discussant.
  72. “Scientific Basis for Current Treatment Options in Pancreatic Cancer.” Pancreatic Cancer Action Network (PanCAN).  Los Angeles, California.  11/11/05.  Invited Speaker.
  73. “Current Management of Pancreatic Neuroendocrine Tumors.” Scripps Clinic Oncology Symposium. San Diego, California.  2/21/06.  Invited Speaker.
  74. “Improving Surgical Outcomes and Quality of Care for Patients with Pancreatic Cancer.”  American Society of Clinical Oncology (ASCO).  Atlanta, Georgia.  6/3/06.  Invited Discussant.
  75. “Aggressive Surgical Approach is Warranted in the Management of Cystic Pancreatic Neoplasms.”  Midwest Surgical Society.  Mackinaw, Michigan.  8/6/06. Invited Discussant.
  76. “Surgical Management and Outcomes of Primary Duodenal Cancer.” Midwest Surgical Society.  Mackinaw, Michigan.  8/6/06. Invited Discussant.
  77. “Preoperative Chemoradiation for Rectal Cancer: Results of Multi-modality Management and Analysis of Prognostic Factors.” Midwest Surgical Society.  Mackinaw, Michigan.  8/6/06. Presenter.
  78. “Investigative Strategies in the Surgical Management of Pancreatic Cancer.” Illinois Surgical Society.  Jackson Hole, Wyoming. 9/16/06  Invited Presenter.
  79. “Scientific Basis for Current Treatment Options in Pancreatic Cancer.” Pancreatic Cancer Action Network (PanCAN).  Los Angeles, California.  11/4/06. Invited Speaker.
  80. “Plasma DNA: A Molecular Marker to Predict Completeness of Resection and Recurrence of Esophageal Carcinoma.”  Western Surgical Association. Cabo, Mexico.  11/13/06.  Invited Discussant.
  81. “National Failure to Operate on Early-Stage Pancreatic Cancer.”  Chicago Surgical Society.  Chicago, Illinois  1/8/07. Presented by resident Karl Bilimoria (Faculty Advisor).
  82. “Intraductal Papillary Mucinous Neoplasms – Surgical Management and Outcomes – A Single Institution Experience.” Central Surgical Association. Chicago, Illinois. 3/09/07. Presented by resident Anthony Yang (Faculty Advisor).
  83. “Surgical Quality and Safety.”  Society of Surgical Oncology, Washington DC. 3/15/07. Presenter and Panel Moderator.
  84. “Surgical Management of Pancreatic Cancer.”  Pancreatic Cancer Action Network (PanCAN). Chicago, IL 3-31-07. Invited Speaker
  85. “The National Failure to Operate on Early-Stage Pancreatic Cancer.”  Pancreas Club, Washington DC, 4-20-07 . Presented by resident Karl Bilimoria (Faculty Advisor).
  86. “Clinicopathologic Features of Pancreatic Neuroendocrine Tumors: Analysis of 9,821 Patients from the National Cancer Database.”  Society of Surgery of the Alimentary Tract.   Washington, DC.  4-23-07 . Presented by resident Karl Bilimoria (Faculty Advisor).
  87. “Combined Modality Treatment for Localized Pancreatic Cancer: The Surgical Perspective.” Evanston-Northwestern Healthcare Department of Medicine Grand Rounds.  Evanston, Illinois.  1-11-08. Invited Speaker
  88. “Resectable, Borderline, and Unresectable Pancreatic Cancer: Definitions and Clinical Criteria.”  American Hepatobiliary and Pancreatic Association Consensus Conference on Localized Pancreatic Cancer.  Orlando, Florida.  1-24-08. Invited Speaker
  89. “A Prospective Single Institution Comparison of Perioperative Outcomes for Laparoscopic and Open Distal Pancreatectomy”  Central Surgical Association, Sarasota, Florida.  3/06/09  (Faculty Advisor).
  90. “Does Surgery Have a Significant Impact on Patients with Pancreatic Cancer?: The Argument for Surgery”  Society for Surgery of the Alimentary Tract, DDW, Chicago, Illinois.  6/03/09.  Invited Speaker.
  91. “Current Standard of Care for Resectable Pancreatic Cancer”  NorthShore Gastrointestinal Oncology Symposium. Chicago, Illinois.  10/09/09.  Invited Speaker.
  92. “Robotic distal pancreatectomy: is it safe and cost effective.”  Central Surgical Association.  Chicago, Illinois. 3/12/10. Invited Discussant.
  93. “The Borderline Resectability Concept.”  American Hepato-Pancreatico-Biliary Association. Miami, Florida. 3/10/12.  Invited Discussant.
  94. “Defining Quality Outcome for Pancreaticoduodenectomy.” Chicago Surgical Society.  Chicago, Illinois.  3/15/12.  (Faculty Advisor).
  95. "Techniques and Results of Vascular Reconstruction in Pancreatic Cancer Surgery.” Society of Surgical Oncology. Orlando, Florida. 3/24/12. Invited Speaker.
  96. Addition of Algenpantucel-L Immunotherapy to Standard Adjuvant Therapy for Pancreatic Cancer: A Phase II Study. Society for Surgery of the Alimentary Tract. San Diego, California. May 22, 2012. (Faculty Advisor).
  97. Cost of Laparoscopic Ischemic Conditioning and Gastric Conduit Morbidity As Compared to a Single Operation. American College of Surgeon Annual Meeting. Chicago, Illinois. October 3, 2012. (Faculty Advisor).
  98. Defining Quality for Pancreaticoduodenectomy: Severe Postoperative Outcomes Including Those Requiring Multiple Readmissions within 90 Days, Prolonged Overall Length of Stays or Multiple Invasive Interventions Are Predictable. . American College of Surgeon Annual Meeting. Chicago, Illinois. October 3, 2012. (Faculty Advisor).
  99. Pearls for Avoiding Complications During Pancreaticoduodenectomy for Pancreatic Cancer. Americas Hepato-Pancreatico-Biliary Association (AHPBA) Annual Meeting. Miami, Florida. February 20, 2014. (Presenter and Panel Discussant).
  100. Optimizing Outcomes for Whipple Procedures: Surgeon or System? Invited Debate. Americas Hepato-Pancreatico-Biliary Association (AHPBA) Annual Meeting. Miami, Florida. February 20, 2014. (Invited Debate Participant).
  101. What to Look for When Seeking Your First Job as an HPB Surgeon. Americas Hepato-Pancreatico-Biliary Association (AHPBA) Annual Meeting. Miami, Florida. February 21, 2014. (Presenter and Panel Discussant).
  102. Octreotide For Pancreas Resections: More Harm Than Good? Americas Hepato-Pancreatico-Biliary Association (AHPBA) Annual Meeting. Miami, Florida. February 21, 2014. Invited Discussant.
  103. Update on Neoadjuvant Therapy for Pancreatic Cancer.  Society of Surgical Oncology Annual Meeting. Phoenix, Arizona. March 14, 2014. Invited Presentation.
  104. The Role of Frozen Section Margin Analysis During Pancreaticoduodenectomy for Pancreatic Cancer. American Surgical Association Annual meeting. Boston, Massachusetts. April 10, 2014 Invited Discussant.
  105. Borderline Resectable Adenocarcinoma of the Pancreas: Definitions and Management. Pancreas Club Annual Meeting. Chicago, Illinois May 2, 2014. (Presenter and Panel Discussant).
  106. Predictors of Survival in Patients with Resectable Gastric Cancer Treated with Neoadjuvant Chemoradiation Therapy and Gastrectomy.  Western Surgical Annual Meeting. Indian Wells, California. November 10, 2014. Invited Discussant.
  107. Invasive Mixed-Type Intraductal Papillary Mucinous Neoplasm: Superior Prognosis Compared to Invasive Main-Duct Intraductal Papillary Mucinous Neoplasm. Central Surgical Annual Meeting. Chicago, Illinois. March 5, 2015. Invited Discussant.
  108. Health System Mergers and Their Effect on Academic Surgery. Society for Surgery of the Alimentary Tract. Washington, DC. May 19th, 2015. (Presenter and Panel Discussant).
  109. Current Management and Future Treatment Strategies for Pancreatic Cancer. AGA Course for Nurse Practitioners and Physician Assistants. Chicago, Illinois. August 16, 2015. (Presenter and Panel Discussant).
  110. Overall Survival Is Increased Among Stage III Pancreatic Adenocarcinoma Patients Receiving Neoadjuvant Chemotherapy Compared to Surgery First and Adjuvant Chemotherapy: An Intention to Treat Analysis of the National Cancer Database. Central Surgical Annual Meeting. Montreal, Canada. March 12, 2016. Invited Discussant.
  111. Investing in a Minimally Invasive Pancreatic Resection Program: The Chairman’s Perspective. Symposium on Minimally Invasive Pancreatic Surgery at the International Hepato-Pancreatico-Biliary Meeting. Sao Paulo, Brazil. April 20, 2016. (Presenter and Panel Discussant).
  112. Great Problems of Our Time: Pancreatic Cancer. International Hepato-Pancreatico-Biliary Meeting. Sao Paulo, Brazil. April 21, 2016. (Presenter and Panel Discussant).
  113. Advances in the Treatment of Borderline and Locally Advanced Pancreatic Cancer. City of Hope International Symposium on Treatment Strategies for Pancreatic Cancer. San Francisco, California. January 18, 2016. (Presenter and Panel Moderator).
  114. Minimally Invasive Pancreatic Resections. Cutting Edge Technologies for Pancreatic Cancer – Global Perspectives. ASCO GI Symposium. San Francisco, California. January 20, 2017. (Presenter and Panel Discussant).
  115. Update on Borderline Resectable Pancreatic Cancer.  Society of Surgical Oncology Annual Meeting. Seattle, Washington. March 17, 2017. (Invited Presentation).
  116. The Business Case for HPB Surgery: Why It Matters. American Hepato-Pancreatico-Biliary Association (AHPBA) Meeting. Miami, Florida. March 8, 2018. (Presenter and Panel Moderator).
  117. Current Management of Colorectal Liver Metastases. Annual Chicago Liver Metastases Symposium. Chicago, Illinois. May 30, 2019. (Panel Moderator).
  118. Management of Neuroendocrine Tumors in 2020. American Hepato-Pancreatico-Biliary Association (AHPBA) Meeting. Miami, Florida. March 8, 2020. (Presenter and Panel Moderator).

Invited Visiting Professorships and Named Lectures:

  • “Current Management of Soft Tissue Sarcomas.” Chicago  Medical School, 2/29/00.  Visiting Professor.
  • “Pancreatic Cancer.” University of Illinois at Chicago, 3/23/00. Visiting Professor.
  • “Pancreatic Cancer.” Monroe Regional Medical Center, Michigan State Medical School, 7/8/00. Visiting Professor.
  • "Pancreatic Cancer.” George Washington University Medical School, 12/08/00. Visiting Professor.
  • “Current Management of Soft Tissue Sarcomas.”  Wayne State Medical School, Detroit, Michigan. 3/21/01. Visiting Professor.
  • “Current Management of Soft Tissue Sarcomas.”  Robert Wood Johnson Medical School, Morristown, New Jersey. 3/28/01. Visiting Professor.
  • “Combined Modality Treatment for Localized Pancreatic Cancer: The Surgical Perspective.” University of New Mexico Cancer Center/Surgical Grand Rounds, Albuquerque, New Mexico. 12/19/03. Visiting Professor.
  • “Surgical Management of Gastroesophageal Junction Tumors.”  William D. Seybold Invited Lectureship. University of Texas Southwestern Medical Center, Dallas, Texas 10/4/06. Visiting Professor.
  • “Borderline Resectable Pancreatic Cancer and the Surgical Management of the Difficult Portal Vein.”  Advances in Cancer Management for the Surgeon.  Harvard Medical School and the Massachusetts General Hospital.  11-08-07. Visiting Professor.
  • “Pearls for Avoiding Complications During Esophagectomy for Esophageal Cancer.”  Advances in Cancer Management for the Surgeon.  Harvard Medical School and the Massachusetts General Hospital.  11-08-07. Visiting Professor.
  • “Lessons Learned and Life After Surgical Fellowship at MD Anderson Cancer Center.”  The Richard G. Martin Distinguished Visiting Professorship at the MD Anderson Cancer Center, Houston, Texas.  5-23-08. Visiting Professor.
  • “Defining Quality and Improving Patient Outcomes for Patients Undergoing Surgery for Pancreas Cancer.” Mayo Clinic, Phoenix, Arizona.   4-1-2013. Visiting Professor
  • “Defining Quality and Improving Patient Outcomes for Patients Undergoing Surgery for Pancreas Cancer.”  The Crachiolo Family Distinguished Visiting Professorship at the University of Florida, Gainesville, Florida.  12-11-2013. Visiting Professor.
  • “Defining Quality and Improving Patient Outcomes for Patients Undergoing Surgery for Pancreas Cancer.”  The J.A. Manning Distinguished Visiting Professorship at Central Michigan University Medical School. 6-5-2015. Visiting Professor.
  • “Defining Quality and Improving Patient Outcomes for Patients Undergoing Surgery for Pancreas Cancer” The Edward G. Mansour Distinguished Visiting Professorship at MetroHealth Medical Center, Department of Surgery, Case Western Reserve University Medical School. 11-22-2014. Visiting Professor
  • "Defining Quality and Improving Patient Outcomes for Patients Undergoing Surgery for Pancreas Cancer”. Loyola University Medical School.1-6-2015. Visiting Professor
  • “Defining Quality and Improving Patient Outcomes for Patients Undergoing Surgery for Pancreas Cancer”. RUSH University Medical School.1-17-2016. Visiting Professor
  • “Assessing Competencies in General Surgery Residency Training” Peking Union Medical College. Beijing, China. 7-5-17. Visiting Professor
  • “Assessment and Quality Improvement of Residency Training”
    Peking Union Medical College. Beijing, China. 7-6-17. Visiting Professor
  • “Current Management of Borderline Resectable Pancreatic Cancer”. Peking Union Medical College. Beijing, China. 7-6-17. Visiting Professor
  • “Faculty Construction and Incentive Systems of Standardized Residency Training.” Zhongshan Hospital of Fudan University. Shanghai, China. 7-8-17. Visiting Professor
  • “Assessing Competencies in General Surgery Residency Training” China. Zhongshan Hospital of Fudan University. Shanghai, China. 7-9-17. Visiting Professor
  • “Improving Outcomes in Patients with Pancreatic Cancer – Major Priorities for the Next Decade” Southern Illinois Medical School. Springfield, Illinois. February 21-22, 2018. Visiting Professor
  • “The Four C’s of Academic Surgery” The Hans Frimpong Annual Spirit of Surgery Lectureship. Department of Surgery. Pritzker School of Medicine, University of Chicago, June 6, 2018. Invited Lecturer
  • “Impact, Insight and Innovation. Our Legacy of Learning” Western Surgical Association. Cabo San Lucas, Mexico. November 4, 2018. Presidential Address
  • "International Evidence-Based Guidelines for Minimally Invasive Pancreatic Resection – The case for MIS Distal Pancreatectomy.” Miami Beach, Florida. March 19, 2019. Invited Lecturer
  • “Leadership for Getting Better in HPB Surgery – State of the Art Lecture.” American Hepato-Pancreatic-Biliary (AHPBA) Annual Meeting. Miami Beach Florida. March 23, 2019. Invited Lecturer

Publications

View more results at PubMed.gov